

Author Index for 1990-91

- Alexandropoulos, K. 35:137
Alliger, R.J. 40:79
Alper, K.R. 35:95
Alvir, J.Ma.J. 35:1
Andreasen, N.C. 40:79, 40:157
Angrist, B. 40:11
Arató, M. 40:91
Arndt, S. 40:79, 40:157
Ashtari, M. 35:1, 40:203
Barocka, A. 40:247
Barouche, F. 40:11
Bartlett, E.J. 40:11, 40:115
Bartzokis, G. 40:239
Baxter, L.R., Jr. 40:195
Beiser, M. 40:21
Berent, S. 35:49
Betley, A.T. 35:49
Biedermann, J. 40:31
Bilder, R.M. 35:1
Blazer, D.G. 40:211
Bogerts, B. 35:1, 40:49, 40:203
Boivin, M.J. 35:49
Boyko, O.B. 40:95
Brodie, J.D. 40:11, 40:115
Brown, G.M. 40:135
Burr, G. 35:39
Camargo, E.E. 40:167
Cantor-Graae, E. 40:253
Casanova, M.F. 35:149
Chabot, R.J. 35:95
Christman, D. 35:39
Cleghorn, J.M. 40:135
Cohen, G.A. 40:79, 40:157
Colter, N. 35:137
Crocq, M.-A. 35:107
Crow, T.J. 35:137
Dauphinais, I.D. 35:137
Degreef, G. 35:1, 40:203
DeLisi, L.E. 35:137
Dewey, S.L. 35:39
Dierks, T. 40:181
Doraiswamy, P.M. 40:95, 40:211
Douglass, A. 40:1
Durst, P. 35:107
Ebert, D. 40:247
Escalona, P.R. 40:95
Feistel, H. 40:247
Figiel, G.S. 40:95
Flekköy, K. 35:27
Fowler, J.S. 35:39
Franco, S. 40:135
Franzén, G. 35:27, 40:253
Frölich, L. 40:181
Garber, H.J. 40:239
Garcia-Rill, E. 40:31
Garnett, E.S. 40:135
Gershon, E.S. 35:137
Gescuk, B. 40:1
Gillespie, H. 40:69
Giordani, B. 35:49
Grady, C.L. 40:221
Grant, C. 40:69
Griswold, V.J. 40:239
Gustafson, L. 35:27
Guze, B.H. 40:195
Harris, G.J. 40:61, 40:167
Harvey, I. 35:61
Hichwa, R.D. 35:49
Hirschowitz, J. 35:39
Hitzemann, R. 35:39
Hollister, L. 40:69
Horwitz, B. 40:221
Husain, M.M. 40:31, 40:95
Iacono, W.G. 40:21
Ihl, R. 40:181
Ingvar, D.H. 40:253
Ivanovic, M. 40:69
Jernigan, T.L. 35:115
John, E.R. 35:95
Joseph, K.C. 35:91
Kaplan, R.D. 40:135
Karlson, S. 35:27
Karson, C.N. 40:31
Kim, A.H. 35:95
Kleinman, J.E. 35:149
Koepp, R.A. 35:49
Krishnan, K.R.R. 40:95, 40:211
Kuhl, D.E. 35:49
Laska, E.M. 40:115
Lieberman, J.A. 35:1, 40:203
Lim, K.O. 35:15, 35:71
Links, J.M. 40:167
Logan, J. 35:39
MacCrimmon, D.J. 40:91
Macher, J.-P. 107
Marder, S.R. 40:239
Mathew, R.J. 40:125
Maurer, K. 40:181
Mazziotta, J.C. 40:195
McDonald, W.M. 40:95, 40:211
McGuffin, P. 35:61
McLaughlin, J.A. 40:49

- Mintz, J. 40:239
Mion, C.C. 40:157
Mitra, T. 40:49
Modell, J.G. 35:49
Mokrani, M.-C. 35:107
Mrak, R.E. 40:31
Mullani, N. 40:69
Murphy, G.M., Jr. 35:15
Na, C. 40:95
Nahmias, C. 40:135
Nasrallah, H.A. 40:49
Nemeroff, C.B. 40:95
Nilsson, A. 35:27
Noga, T. 40:61
Oldendorf, W.H. 40:239
Olson, S.C. 40:49
Pearlson, G.D. 40:61, 40:167
Perisic, I. 40:181
Pfefferbaum, A. 35:15, 35:71, 35:115
Phelps, M.E. 40:195
Pietrini, P. 40:221
Prichep, L.S. 35:95
Rapoport, J.L. 40:221
Rapoport, S.I. 40:221
RheW, E.H. 40:61
Risberg, J. 35:27, 40:253
Rodriguez, G. 35:27
Rosenbloom, M.J. 35:115
Rothley, J.M. 35:49
Rotrosen, J. 40:11
Sanfilipo, M. 40:115
Schapiro, M.B. 40:221
Schlyer, D. 35:39
Schuff, N. 35:107
Schwartz, J.M. 40:195
Schwarzkopf, S.B. 40:49
Sitaram, N. 35:91
Skinner, R.D. 40:31
Sponheim, S.R. 40:21
Stevens, J.R. 35:149
Sullivan, E.V. 35:115
Swayze, V.W. II 40:79, 40:157
Swedo, S.E. 40:221
Szechtman, B. 40:135
Szechtman, H. 40:135
Szuba, M.P. 40:195
Szymanski, S. 40:203
Tancredi, 40:69
Tinklenberg, J.R. 35:115
Toone, B.K. 35:61
Tuma, I. 35:137
Vitkun, S. 35:39
Volkow, N.D. 35:39, 40:69
Warkentin, S. 35:27, 40:253
Wiesel, F.-A. 40:101
Wik, G. 40:101
Williams, W. 35:61
Wilson, W.H. 40:125
Wolf, A.P. 35:39, 40:11, 40:115
Wolkin, A. 40:11, 40:115
Woods, B.T. 40:1
Yesavage, J.A. 35:115
Zipursky, R.B. 35:15, 35:71, 35:115
Zito, J. 40:203

Subject Index for 1990-91

Affective disorder

aging, late onset, 40:211
aging, magnetic resonance imaging, 40:211
aging, mania, 40:211
aging, subcortical hyperintensities, 40:211
Alzheimer's disease, frontal lobe, 40:195
Alzheimer's disease, glucose metabolism, 40:195
Alzheimer's disease, hippocampus, 40:195
Alzheimer's disease, positron emission tomography, 40:195
basal ganglia, limbic system, 40:95
basal ganglia, magnetic resonance imaging, 40:95
basal ganglia, putamen, 40:95
electroencephalographic topography, serotonin, 40:91
frontal lobe, Alzheimer's disease, 40:195
frontal lobe, glucose metabolism, 40:195
frontal lobe, hexamethylpropyleneamineoxime (HMPAO), 40:247
frontal lobe, hippocampus, 40:195
frontal lobe, limbic system, 40:247
frontal lobe, positron emission tomography, 40:195
frontal lobe, single photon emission computed tomography, 40:247
frontal lobe, sleep deprivation, 40:247
glucose metabolism, Alzheimer's disease, 40:195
glucose metabolism, frontal lobe, 40:195
glucose metabolism, hippocampus, 40:195
glucose metabolism, positron emission tomography, 40:195
hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
hippocampus, Alzheimer's disease, 40:195
hippocampus, frontal lobe, 40:195
hippocampus, glucose metabolism, 40:195
hippocampus, positron emission tomography, 40:195
late onset, aging, 40:211
late onset, magnetic resonance imaging, 40:211
late onset, mania, 40:211

Affective disorder continued

late onset, subcortical hyperintensities, 40:211
limbic system, basal ganglia, 40:95
limbic system, hexamethylpropyleneamineoxime (HMPAO), 40:247
limbic system, magnetic resonance imaging, 40:95
limbic system, putamen, 40:95
limbic system, single photon emission computed tomography, 40:247
limbic system, sleep deprivation, 40:247
magnetic resonance imaging, aging, 40:211
magnetic resonance imaging, basal ganglia, 40:95
magnetic resonance imaging, late onset, 40:211
magnetic resonance imaging, limbic system, 40:95
magnetic resonance imaging, mania, 40:211
magnetic resonance imaging, putamen, 40:95
magnetic resonance imaging, subcortical hyperintensities, 40:211
mania, aging, 40:211
mania, late onset, 40:211
mania, magnetic resonance imaging, 40:211
mania, subcortical hyperintensities, 40:211
positron emission tomography, Alzheimer's disease, 40:195
positron emission tomography, frontal lobe, 40:195
positron emission tomography, glucose metabolism, 40:195
positron emission tomography, hippocampus, 40:195
putamen, basal ganglia, 40:95
putamen, limbic system, 40:95
putamen, magnetic resonance imaging, 40:95
serotonin, electroencephalographic topography, 40:91
sleep, frontal lobe, 40:247
sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep, limbic system, 40:247
sleep, single photon emission computed tomography, 40:247
sleep deprivation, frontal lobe, 40:247
sleep deprivation, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep deprivation, limbic system, 40:247
sleep deprivation, single photon emission computed tomography, 40:247

Affective disorder continued

single photon emission computed tomography, frontal lobe, 40:247

single photon emission computed tomography, hexamethylpropyleneamineoxime (HMPAO), 40:247

single photon emission computed tomography, limbic system, 40:247

single photon emission computed tomography, sleep deprivation, 40:247

subcortical hyperintensities, aging, 40:211

subcortical hyperintensities, late onset, 40:211

subcortical hyperintensities, magnetic resonance imaging, 40:211

subcortical hyperintensities, mania, 40:211

Aging

affective disorder, late onset, 40:211

affective disorder, magnetic resonance imaging, 40:211

affective disorder, mania, 40:211

affective disorder, subcortical hyperintensities, 40:211

Alzheimer's disease, cognition, 35:115

Alzheimer's disease, computed tomography, 35:115

Alzheimer's disease, Mini-Mental State Examination, 35:115

Alzheimer's disease, ventricular size, 35:115

Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115

brain size, magnetic resonance imaging, 40:61

cognition, Alzheimer's disease, 35:115

cognition, computed tomography, 35:115

cognition, Mini-Mental State Examination, 35:115

cognition, ventricular size, 35:115

cognition, Wechsler Adult Intelligence Scale, 35:115

computed tomography, Alzheimer's disease, 35:115

computed tomography, cognition, 35:115

computed tomography, Mini-Mental State Examination, 35:115

computed tomography, ventricular size, 35:115

computed tomography, Wechsler Adult Intelligence Scale, 35:115

hippocampus, magnetic resonance imaging, 35:15

hippocampus, ventricular size, 35:15

late onset, affective disorder, 40:211

late onset, magnetic resonance imaging, 40:211

Aging continued

late onset, mania, 40:211

late onset, subcortical hyperintensities, 40:211

limbic system, magnetic resonance imaging, 35:15

limbic system, ventricular size, 35:15

magnetic resonance imaging, affective disorder, 40:211

magnetic resonance imaging, brain size, 40:61

magnetic resonance imaging, hippocampus, 35:15

magnetic resonance imaging, late onset, 40:211

magnetic resonance imaging, limbic system, 35:15

magnetic resonance imaging, mania, 40:211

magnetic resonance imaging, subcortical hyperintensities, 40:211

magnetic resonance imaging, ventricular size, 35:15

mania, affective disorder, 40:211

mania, late onset, 40:211

mania, magnetic resonance imaging, 40:211

mania, subcortical hyperintensities, 40:211

Mini-Mental State Examination, Alzheimer's disease, 35:115

Mini-Mental State Examination, cognition, 35:115

Mini-Mental State Examination, computed tomography, 35:115

Mini-Mental State Examination, ventricular size, 35:115

subcortical hyperintensities, affective disorder, 40:211

subcortical hyperintensities, late onset, 40:211

subcortical hyperintensities, magnetic resonance imaging, 40:211

subcortical hyperintensities, mania, 40:211

ventricular size, Alzheimer's disease, 35:115

ventricular size, cognition, 35:115

ventricular size, computed tomography, 35:115

ventricular size, hippocampus, 35:15

ventricular size, limbic system, 35:15

ventricular size, magnetic resonance imaging, 35:15

ventricular size, Mini-Mental State Examination, 35:115

ventricular size, Wechsler Adult Intelligence Scale, 35:115

Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115

Aging continued

- Wechsler Adult Intelligence Scale, cognition, 35:115
- Wechsler Adult Intelligence Scale, computed tomography, 35:115
- Wechsler Adult Intelligence Scale, ventricular size, 35:115

Alcohol. See Ethanol**Alcoholism**

- computed tomography, measurement reliability, 40:1
- measurement reliability, computed tomography, 40:1
- ventricle-brain ratio, computed tomography, 40:1

Alzheimer's disease

- affective disorder, frontal lobe, 40:195
- affective disorder, glucose metabolism, 40:195
- affective disorder, hippocampus, 40:195
- affective disorder, positron emission tomography, 40:195
- aging, cognition, 35:115
- aging, computed tomography, 35:115
- aging, Mini-Mental State Examination, 35:115
- aging, ventricular size, 35:115
- aging, Wechsler Adult Intelligence Scale, 35:115
- astrocytosis, dentate gyrus, 35:149
- astrocytosis, entorhinal cortex, 35:149
- astrocytosis, hippocampus, 35:149
- astrocytosis, post-mortem examination, 35:149
- astrocytosis, schizophrenia, 35:149
- blood flow, cortical circumferential analysis, 40:167
- blood flow, iodoamphetamine, 40:167
- blood flow, single photon emission computed tomography, 40:167
- brain size, magnetic resonance imaging, 40:61
- cognition, aging, 35:115
- cognition, computed tomography, 35:115
- cognition, Mini-Mental State Examination, 35:115
- cognition, ventricular size, 35:115
- cognition, Wechsler Adult Intelligence Scale, 35:115
- computed tomography, aging, 35:115
- computed tomography, cognition, 35:115
- computed tomography, Mini-Mental State Examination, 35:115
- computed tomography, neuropsychology, 35:115

Alzheimer's disease continued

- computed tomography, ventricular size, 35:115
- computed tomography, Wechsler Adult Intelligence Scale, 35:115
- cortical circumferential analysis, blood flow, 40:167
- cortical circumferential analysis, iodoamphetamine, 40:167
- cortical circumferential analysis, single photon emission computed tomography, 40:167
- dentate gyrus, astrocytosis, 35:149
- dentate gyrus, entorhinal cortex, 35:149
- dentate gyrus, hippocampus, 35:149
- dentate gyrus, post-mortem examination, 35:149
- dentate gyrus, schizophrenia, 35:149
- electroencephalographic topography, neuropsychology, 40:181
- electroencephalographic topography, severity of dementia, 40:181
- entorhinal cortex, astrocytosis, 35:149
- entorhinal cortex, dentate gyrus, 35:149
- entorhinal cortex, hippocampus, 35:149
- entorhinal cortex, post-mortem examination, 35:149
- entorhinal cortex, schizophrenia, 35:149
- frontal lobe, affective disorder, 40:195
- frontal lobe, glucose metabolism, 40:195
- frontal lobe, hippocampus, 40:195
- frontal lobe, positron emission tomography, 40:195
- glucose metabolism, affective disorder, 40:195
- glucose metabolism, frontal lobe, 40:195
- glucose metabolism, hippocampus, 40:195
- glucose metabolism, positron emission tomography, 40:195
- hippocampus, affective disorder, 40:195
- hippocampus, astrocytosis, 35:149
- hippocampus, dentate gyrus, 35:149
- hippocampus, entorhinal cortex, 35:149
- hippocampus, frontal lobe, 40:195
- hippocampus, glucose metabolism, 40:195
- hippocampus, positron emission tomography, 40:195
- hippocampus, post-mortem examination, 35:149
- hippocampus, schizophrenia, 35:149
- iodoamphetamine, blood flow, 40:167
- iodoamphetamine, cortical circumferential analysis, 40:167
- iodoamphetamine, single photon emission computed tomography, 40:167

Alzheimer's disease continued

- magnetic resonance imaging, brain size, 40:61
- Mini-Mental State Examination, aging, 35:115
- Mini-Mental State Examination, cognition, 35:115
- Mini-Mental State Examination, computed tomography, 35:115
- Mini-Mental State Examination, ventricular size, 35:115
- Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
- neuropsychology, computed tomography, 35:115
- neuropsychology, electroencephalographic topography, 40:181
- neuropsychology, severity of dementia, 40:181
- positron emission tomography, affective disorder, 40:195
- positron emission tomography, frontal lobe, 40:195
- positron emission tomography, glucose metabolism, 40:195
- positron emission tomography, hippocampus, 40:195
- post-mortem examination, astrocytosis, 35:149
- post-mortem examination, dentate gyrus, 35:149
- post-mortem examination, entorhinal cortex, 35:149
- post-mortem examination, hippocampus, 35:149
- post-mortem examination, schizophrenia, 35:149
- schizophrenia, astrocytosis, 35:149
- schizophrenia, dentate gyrus, 35:149
- schizophrenia, entorhinal cortex, 35:149
- schizophrenia, hippocampus, 35:149
- schizophrenia, post-mortem examination, 35:149
- severity of dementia, electroencephalographic topography, 40:181
- severity of dementia, neuropsychology, 40:181
- single photon emission computed tomography, blood flow, 40:167
- single photon emission computed tomography, cortical circumferential analysis, 40:167
- single photon emission computed tomography, iodoamphetamine, 40:167

Alzheimer's disease continued

- ventricular size, aging, 35:115
- ventricular size, cognition, 35:115
- ventricular size, computed tomography, 35:115
- ventricular size, Mini-Mental State Examination, 35:115
- ventricular size, Wechsler Adult Intelligence Scale, 35:115
- Wechsler Adult Intelligence Scale, aging, 35:115
- Wechsler Adult Intelligence Scale, cognition, 35:115
- Wechsler Adult Intelligence Scale, computed tomography, 35:115
- Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115
- Wechsler Adult Intelligence Scale, ventricular size, 35:115
- Amygdala**
- genetics, hippocampus, 35:137
- genetics, magnetic resonance imaging, 35:137
- genetics, schizophrenia, 35:137
- genetics, temporal lobe, 35:137
- genetics, ventricular size, 35:137
- hippocampus, genetics, 35:137
- hippocampus, magnetic resonance imaging, 35:1, 35:137
- hippocampus, schizophrenia, 35:1, 35:137
- hippocampus, temporal horn volume, 35:1
- hippocampus, temporal lobe, 35:1, 35:137
- hippocampus, ventricular size, 35:137
- magnetic resonance imaging, genetics, 35:137
- magnetic resonance imaging, hippocampus, 35:1, 35:137
- magnetic resonance imaging, schizophrenia, 35:1, 35:137
- magnetic resonance imaging, temporal horn volume, 35:1
- magnetic resonance imaging, temporal lobe, 35:1, 35:137
- magnetic resonance imaging, ventricular size, 35:137
- schizophrenia, genetics, 35:137
- schizophrenia, hippocampus, 35:1, 35:137
- schizophrenia, magnetic resonance imaging, 35:1, 35:137
- schizophrenia, temporal horn volume, 35:1
- schizophrenia, temporal lobe, 35:1, 35:137
- schizophrenia, ventricular size, 35:137
- temporal horn volume, hippocampus, 35:1
- temporal horn volume, magnetic resonance imaging, 35:1

Amygdala continued

temporal horn volume, schizophrenia, 35:1
 temporal lobe, genetics, 35:137
 temporal lobe, hippocampus, 35:1, 35:137
 temporal lobe, magnetic resonance imaging, 35:1, 35:137

temporal lobe, schizophrenia, 35:1, 35:137
 temporal lobe, ventricular size, 35:137
 ventricular size, genetics, 35:137
 ventricular size, hippocampus, 35:137
 ventricular size, magnetic resonance imaging, 35:137

ventricular size, schizophrenia, 35:137
 ventricular size, temporal lobe, 35:137

Anxiety

blood flow, diazepam, 40:125

blood flow, generalized anxiety disorder, 40:125

blood flow, ondansetron, 40:125

diazepam, blood flow, 40:125

diazepam, generalized anxiety disorder, 40:125

diazepam, ondansetron, 40:125

frontal lobe, glucose metabolism, 35:49
 40:101

frontal lobe, homovanillic acid, 40:101

frontal lobe, laterality, 35:49

frontal lobe, positron emission tomography, 35:49, 40:101

frontal lobe, prolactin, 40:101

frontal lobe, schizophrenia, 40:101

frontal lobe, State-Trait Anxiety Inventory, 35:49

generalized anxiety disorder, blood flow, 40:125

generalized anxiety disorder, diazepam, 40:125

generalized anxiety disorder, ondansetron, 40:125

glucose metabolism, frontal lobe, 35:49, 40:101

glucose metabolism, homovanillic acid, 40:101

glucose metabolism, laterality, 35:49

glucose metabolism, positron emission tomography, 35:49, 40:101

glucose metabolism, prolactin, 40:101

glucose metabolism, schizophrenia, 40:101

glucose metabolism, State-Trait Anxiety Inventory, 35:49

homovanillic acid, frontal lobe, 40:101

homovanillic acid, glucose metabolism, 40:101

homovanillic acid, positron emission tomography, 40:101

Anxiety continued

homovanillic acid, prolactin, 40:101

homovanillic acid, schizophrenia, 40:101

laterality, frontal lobe, 35:49

laterality, glucose metabolism, 35:49

laterality, positron emission tomography, 35:49

laterality, State-Trait Anxiety Inventory, 35:49

ondansetron, blood flow, 40:125

ondansetron, diazepam, 40:125

ondansetron, generalized anxiety disorder, 40:125

positron emission tomography, frontal lobe, 35:49, 40:101

positron emission tomography, glucose metabolism, 35:49, 40:101

positron emission tomography, homovanillic acid, 40:101

positron emission tomography, laterality, 35:49

positron emission tomography, prolactin, 40:101

positron emission tomography, schizophrenia, 40:101

positron emission tomography, State-Trait Anxiety Inventory, 35:49

prolactin, frontal lobe, 40:101

prolactin, glucose metabolism, 40:101

prolactin, homovanillic acid, 40:101

prolactin, positron emission tomography, 40:101

prolactin, schizophrenia, 40:101

schizophrenia, frontal lobe, 40:101

schizophrenia, glucose metabolism, 40:101

schizophrenia, homovanillic acid, 40:101

schizophrenia, positron emission tomography, 40:101

schizophrenia, prolactin, 40:101

State-Trait Anxiety Inventory, frontal lobe, 35:49

State-Trait Anxiety Inventory, glucose metabolism, 35:49

State-Trait Anxiety Inventory, laterality, 35:49

State-Trait Anxiety Inventory, positron emission tomography, 35:49

Apomorphine

frontal lobe, glucose metabolism, 40:135

frontal lobe, never-medicated patients, 40:135

frontal lobe, positron emission tomography, 40:135

frontal lobe, schizophrenia, 40:135

Apomorphine continued

frontal lobe, temporal lobe, 40:135
 glucose metabolism, frontal lobe, 40:135
 glucose metabolism, never-medicated patients, 40:135
 glucose metabolism, positron emission tomography, 40:135
 glucose metabolism, schizophrenia, 40:135
 glucose metabolism, temporal lobe, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, glucose metabolism, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, schizophrenia, 40:135
 never-medicated patients, temporal lobe, 40:135
 positron emission tomography, frontal lobe, 40:135
 positron emission tomography, glucose metabolism, 40:135
 positron emission tomography, never-medicated patients, 40:135
 positron emission tomography, schizophrenia, 40:135
 positron emission tomography, temporal lobe, 40:135
 schizophrenia, frontal lobe, 40:135
 schizophrenia, glucose metabolism, 40:135
 schizophrenia, never-medicated patients, 40:135
 schizophrenia, positron emission tomography, 40:135
 schizophrenia, temporal lobe, 40:135
 temporal lobe, frontal lobe, 40:135
 temporal lobe, glucose metabolism, 40:135
 temporal lobe, never-medicated patients, 40:135
 temporal lobe, positron emission tomography, 40:135
 temporal lobe, schizophrenia, 40:135

Arecoline

electroencephalographic topography, polysomnography, 35:91
 electroencephalographic topography, sleep, 35:91
 polysomnography, electroencephalographic topography, 35:91
 sleep, electroencephalographic topography, 35:91

Basal ganglia

affective disorder, limbic system, 40:95

Basal ganglia continued

affective disorder, magnetic resonance imaging, 40:95
 affective disorder, putamen, 40:95
 frontal lobe, glucose, 40:115
 frontal lobe, neuroleptics, 40:115
 frontal lobe, positron emission tomography, 40:115
 frontal lobe, schizophrenia, 40:115
 glucose, frontal lobe, 40:115
 glucose, neuroleptics, 40:115
 glucose, positron emission tomography, 40:115
 glucose, schizophrenia, 40:115
 limbic system, affective disorder, 40:95
 limbic system, magnetic resonance imaging, 40:95
 limbic system, putamen, 40:95
 magnetic resonance imaging, affective disorder, 40:95
 magnetic resonance imaging, limbic system, 40:95
 magnetic resonance imaging, putamen, 40:95
 magnetic resonance imaging, schizophrenia, 40:157
 magnetic resonance imaging, tardive dyskinesia, 40:157
 neuroleptics, frontal lobe, 40:115
 neuroleptics, glucose, 40:115
 neuroleptics, positron emission tomography, 40:115
 neuroleptics, schizophrenia, 40:115
 positron emission tomography, frontal lobe, 40:115
 positron emission tomography, glucose, 40:115
 positron emission tomography, neuroleptics, 40:115
 positron emission tomography, schizophrenia, 40:115
 putamen, affective disorder, 40:95
 putamen, limbic system, 40:95
 putamen, magnetic resonance imaging, 40:95
 schizophrenia, frontal lobe, 40:115
 schizophrenia, glucose, 40:115
 schizophrenia, magnetic resonance imaging, 40:157
 schizophrenia, neuroleptics, 40:115
 schizophrenia, positron emission tomography, 40:115
 schizophrenia, tardive dyskinesia, 40:157
 tardive dyskinesia, magnetic resonance imaging, 40:157
 tardive dyskinesia, schizophrenia, 40:157

Benzodiazepine. See Diazepam

Blood flow

Alzheimer's disease, cortical circumferential analysis, 40:167
 Alzheimer's disease, iodoamphetamine, 40:167
 Alzheimer's disease, single photon emission computed tomography, 40:167
 anxiety, diazepam, 40:125
 anxiety, ondansetron, 40:125
 Chicago Word Fluency Test, neuropsychology, 40:253
 cortical circumferential analysis, Alzheimer's disease, 40:167
 cortical circumferential analysis, iodoamphetamine, 40:167
 cortical circumferential analysis, single photon emission computed tomography, 40:167
 diazepam, anxiety, 40:125
 diazepam, generalized anxiety disorder, 40:125
 diazepam, ondansetron, 40:125
 frontal lobe, long-term followup, 40:253
 frontal lobe, schizophrenia, 35:27, 40:253
 frontal lobe, symptom severity, 35:27
 generalized anxiety disorder, diazepam, 40:125
 generalized anxiety disorder, ondansetron, 40:125
 iodoamphetamine, Alzheimer's disease, 40:167
 iodoamphetamine, cortical circumferential analysis, 40:167
 iodoamphetamine, single photon emission computed tomography, 40:167
 long-term followup, frontal lobe, 40:253
 long-term followup, schizophrenia, 40:253
 neuropsychology, Chicago Word Fluency Test, 40:253
 neuropsychology, schizophrenia, 40:253
 neuropsychology, Wisconsin Card Sort Test, 40:253
 ondansetron, anxiety, 40:125
 ondansetron, diazepam, 40:125
 ondansetron, generalized anxiety disorder, 40:125
 schizophrenia, frontal lobe, 35:27, 40:253
 schizophrenia, long-term followup, 40:253
 schizophrenia, neuropsychology, 40:253
 schizophrenia, symptom severity, 35:27
 schizophrenia, Wisconsin Card Sort Test, 40:253
 single photon emission computed tomography, Alzheimer's disease, 40:167
 single photon emission computed tomography, cortical circumferential analysis, 40:167

Blood flow continued

single photon emission computed tomography, iodoamphetamine, 40:167
 symptom severity, frontal lobe, 35:27
 symptom severity, schizophrenia, 35:27
 Wisconsin Card Sort Test, neuropsychology, 40:253
 Wisconsin Card Sort Test, schizophrenia, 40:253

Brain electrical activity mapping. See electroencephalographic topography

Brain stem

locus ceruleus, neuropathology, 40:31
 locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 locus ceruleus, pedunclopontine nucleus, 40:31
 locus ceruleus, schizophrenia, 40:31
 neuropathology, locus ceruleus, 40:31
 neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
 neuropathology, pedunclopontine nucleus, 40:31
 neuropathology, schizophrenia, 40:31
 nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
 nicotinamide adenosine dinucleotide phosphate, pedunclopontine nucleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
 pedunclopontine nucleus, locus ceruleus, 40:31
 pedunclopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 pedunclopontine nucleus, neuropathology, 40:31
 pedunclopontine nucleus, schizophrenia, 40:31
 schizophrenia, locus ceruleus, 40:31
 schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
 schizophrenia, neuropathology, 40:31
 schizophrenia, pedunclopontine nucleus, 40:31

Brain volume

computer methods, magnetic resonance imaging, 40:61
 magnetic resonance imaging, computer methods, 40:61

Cerebral blood flow. See Blood flow

Clomipramine

electroencephalographic topography, evoked potentials, 40:91
 electroencephalographic topography, fluoxetine, 40:91

Clomipramine continued

- electroencephalographic topography, laterality, 40:91
- electroencephalographic topography, P300, 40:91
- electroencephalographic topography, serotonin, 40:91
- evoked potentials, electroencephalographic topography, 40:91
- evoked potentials, fluoxetine, 40:91
- evoked potentials, laterality, 40:91
- evoked potentials, P300, 40:91
- evoked potentials, serotonin, 40:91
- fluoxetine, electroencephalographic topography, 40:91
- fluoxetine, evoked potentials, 40:91
- fluoxetine, laterality, 40:91
- fluoxetine, P300, 40:91
- fluoxetine, serotonin, 40:91
- laterality, electroencephalographic topography, 40:91
- laterality, evoked potentials, 40:91
- laterality, fluoxetine, 40:91
- laterality, P300, 40:91
- laterality, serotonin, 40:91
- P300, electroencephalographic topography, 40:91
- P300, evoked potentials, 40:91
- P300, fluoxetine, 40:91
- P300, laterality, 40:91
- P300, serotonin, 40:91
- serotonin, electroencephalographic topography, 40:91
- serotonin, evoked potentials, 40:91
- serotonin, fluoxetine, 40:91
- serotonin, laterality, 40:91
- serotonin, P300, 40:91

Cocaine

- alpha power, Beck Depression Scale, 35:95
- alpha power, electroencephalographic topography, 35:95
- alpha power, substance abuse, 35:95
- Beck Depression Scale, alpha power, 35:95
- Beck Depression Scale, electroencephalographic topography, 35:95
- Beck Depression Scale, substance abuse, 35:95
- electroencephalographic topography, alpha power, 35:95
- electroencephalographic topography, Beck Depression Scale, 35:95
- electroencephalographic topography, substance abuse, 35:95

Cocaine continued

- substance abuse, alpha power, 35:95
- substance abuse, Beck Depression Scale, 35:95
- substance abuse, electroencephalographic topography, 35:95
- Cognition**
- Alzheimer's disease, Brief Cognitive Rating Scale, 40:181
- Alzheimer's disease, electroencephalographic topography, 40:181
- Brief Cognitive Rating Scale, Alzheimer's disease, 40:181
- Brief Cognitive Rating Scale, electroencephalographic topography, 40:181
- electroencephalographic topography, Alzheimer's disease, 40:181
- electroencephalographic topography, Brief Cognitive Rating Scale, 40:181
- Computed tomography**
- admixture analysis, genetics, 35:61
- admixture analysis, schizophrenia, 35:61
- admixture analysis, ventricle-brain ratio, 35:61
- aging, Alzheimer's disease, 35:115
- aging, cognition, 35:115
- aging, Mini-Mental State Examination, 35:115
- aging, ventricular size, 35:115
- aging, Wechsler Adult Intelligence Scale, 35:115
- alcoholism, measurement reliability, 40:1
- alcoholism, ventricle-brain ratio, 40:1
- Alzheimer's disease, aging, 35:115
- Alzheimer's disease, cognition, 35:115
- Alzheimer's disease, Mini-Mental State Examination, 35:115
- Alzheimer's disease, neuropsychology, 35:115
- Alzheimer's disease, ventricular size, 35:115
- Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115
- cerebral asymmetry, laterality, 35:71
- cerebral asymmetry, measurement methods, 35:71
- cognition, aging, 35:115
- cognition, Alzheimer's disease, 35:115
- cognition, Mini-Mental State Examination, 35:115
- cognition, ventricular size, 35:115
- cognition, Wechsler Adult Intelligence Scale, 35:115
- genetics, admixture analysis, 35:61

Computed tomography continued
 genetics, schizophrenia, 35:61
 genetics, ventricle-brain ratio, 35:61
 laterality, cerebral asymmetry, 35:71
 laterality, measurement methods, 35:71
 measurement methods, cerebral asymmetry, 35:71
 measurement methods, laterality, 35:71
 measurement reliability, alcoholism, 40:1
 measurement reliability, ventricle-brain ratio, 40:1
 Mini-Mental State Examination, aging, 35:115
 Mini-Mental State Examination, Alzheimer's disease, 35:115
 Mini-Mental State Examination, cognition, 35:115
 Mini-Mental State Examination, ventricular size, 35:115
 Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
 neuropsychology, Alzheimer's disease, 35:115
 occipital horn size, reliability, 40:21
 reliability, occipital horn size, 40:21
 schizophrenia, admixture analysis, 35:61
 schizophrenia, genetics, 35:61
 schizophrenia, stability after psychosis onset, 40:21
 schizophrenia, ventricle-brain ratio, 35:61
 schizophrenia, ventricular size, 40:21
 stability after psychosis onset, schizophrenia, 40:21
 stability after psychosis onset, ventricular size, 40:21
 ventricle-brain ratio, admixture analysis, 35:61
 ventricle-brain ratio, alcoholism, 40:1
 ventricle-brain ratio, genetics, 35:61
 ventricle-brain ratio, measurement reliability, 40:1
 ventricle-brain ratio, schizophrenia, 35:61
 ventricular size, aging, 35:115
 ventricular size, Alzheimer's disease, 35:115
 ventricular size, cognition, 35:115
 ventricular size, Mini-Mental State Examination, 35:115
 ventricular size, schizophrenia, 40:21
 ventricular size, stability after psychosis onset, 40:21
 ventricular size, Wechsler Adult Intelligence Scale, 35:115
 Wechsler Adult Intelligence Scale, aging, 35:115

Computed tomography continued
 Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115
 Wechsler Adult Intelligence Scale, cognition, 35:115
 Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115
 Wechsler Adult Intelligence Scale, ventricular size, 35:115
Crack. See Cocaine
Depression. See Affective disorder
Diazepam
 anxiety, blood flow, 40:125
 anxiety, generalized anxiety disorder, 40:125
 anxiety, ondansetron, 40:125
 blood flow, anxiety, 40:125
 blood flow, generalized anxiety disorder, 40:125
 blood flow, ondansetron, 40:125
 generalized anxiety disorder, anxiety, 40:125
 generalized anxiety disorder, blood flow, 40:125
 generalized anxiety disorder, ondansetron, 40:125
 ondansetron, anxiety, 40:125
 ondansetron, blood flow, 40:125
 ondansetron, generalized anxiety disorder, 40:125
Dorsolateral prefrontal cortex. See Frontal lobe
Electroencephalographic topography
 affective disorder, serotonin, 40:91
 alpha power, Beck Depression Scale, 35:95
 alpha power, cocaine, 35:95
 alpha power, substance abuse, 35:95
 Alzheimer's disease, Brief Cognitive Rating Scale, 40:181
 Alzheimer's disease, cognition, 40:181
 Alzheimer's disease, neuropsychology, 40:181
 Alzheimer's disease, severity of dementia, 40:181
 arecoline, polysomnography, 35:91
 arecoline, sleep, 35:91
 Beck Depression Scale, alpha power, 35:95
 Beck Depression Scale, cocaine, 35:95
 Beck Depression Scale, substance abuse, 35:95
 Brief Cognitive Rating Scale, Alzheimer's disease, 40:181
 Brief Cognitive Rating Scale, cognition, 40:181
 clomipramine, evoked potentials, 40:91
 clomipramine, fluoxetine, 40:91

Electroencephalographic topography
continued

clomipramine, laterality, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 cocaine, alpha power, 35:95
 cocaine, Beck Depression Scale, 35:95
 cocaine, substance abuse, 35:95
 cognition, Alzheimer's disease, 40:181
 cognition, Brief Cognitive Rating Scale, 40:181
 evoked potentials, clomipramine, 40:91
 evoked potentials, fluoxetine, 40:91
 evoked potentials, laterality, 40:91
 evoked potentials, P300, 40:91
 evoked potentials, serotonin, 40:91
 fluoxetine, clomipramine, 40:91
 fluoxetine, evoked potentials, 40:91
 fluoxetine, laterality, 40:91
 fluoxetine, P300, 40:91
 fluoxetine, serotonin, 40:91
 laterality, clomipramine, 40:91
 laterality, evoked potentials, 40:91
 laterality, fluoxetine, 40:91
 laterality, P300, 40:91
 laterality, serotonin, 40:91
 neuropsychology, Alzheimer's disease, 40:181
 neuropsychology, severity of dementia, 40:181
 P300, clomipramine, 40:91
 P300, evoked potentials, 40:91
 P300, fluoxetine, 40:91
 P300, laterality, 40:91
 P300, serotonin, 40:91
 polysomnography, arecoline, 35:91
 serotonin, affective disorder, 40:91
 serotonin, clomipramine, 40:91
 serotonin, evoked potentials, 40:91
 serotonin, fluoxetine, 40:91
 serotonin, laterality, 40:91
 serotonin, P300, 40:91
 severity of dementia, Alzheimer's disease, 40:181
 severity of dementia, neuropsychology, 40:181
 sleep, arecoline, 35:91
 substance abuse, alpha power, 35:95
 substance abuse, Beck Depression Scale, 35:95
 substance abuse, cocaine, 35:95

Ethanol

glucose metabolism, positron emission tomography, 35:39

Ethanol continued

positron emission tomography, glucose metabolism, 35:39

Evoked potential

clomipramine, electroencephalographic topography, 40:91
 clomipramine, fluoxetine, 40:91
 clomipramine, laterality, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 electroencephalographic topography, clomipramine, 40:91
 electroencephalographic topography, fluoxetine, 40:91
 electroencephalographic topography, laterality, 40:91
 electroencephalographic topography, P300, 40:91
 electroencephalographic topography, serotonin, 40:91
 fluoxetine, clomipramine, 40:91
 fluoxetine, electroencephalographic topography, 40:91
 fluoxetine, laterality, 40:91
 fluoxetine, P300, 40:91
 fluoxetine, serotonin, 40:91
 laterality, clomipramine, 40:91
 laterality, electroencephalographic topography, 40:91
 laterality, fluoxetine, 40:91
 laterality, P300, 40:91
 laterality, serotonin, 40:91
 P300, clomipramine, 40:91
 P300, electroencephalographic topography, 40:91
 P300, fluoxetine, 40:91
 P300, laterality, 40:91
 P300, serotonin, 40:91
 serotonin, clomipramine, 40:91
 serotonin, electroencephalographic topography, 40:91
 serotonin, fluoxetine, 40:91
 serotonin, laterality, 40:91
 serotonin, P300, 40:91
Fluoxetine
 clomipramine, electroencephalographic topography, 40:91
 clomipramine, evoked potentials, 40:91
 clomipramine, laterality, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 electroencephalographic topography, clomipramine, 40:91
 electroencephalographic topography, evoked

Fluoxetine continued

- potentials, 40:91
- electroencephalographic topography, laterality, 40:91
- electroencephalographic topography, P300, 40:91
- electroencephalographic topography, serotonin, 40:91
- evoked potentials, clomipramine, 40:91
- evoked potentials, electroencephalographic topography, 40:91
- evoked potentials, laterality, 40:91
- evoked potentials, P300, 40:91
- evoked potentials, serotonin, 40:91
- laterality, clomipramine, 40:91
- laterality, electroencephalographic topography, 40:91
- laterality, evoked potentials, 40:91
- laterality, P300, 40:91
- laterality, serotonin, 40:91
- P300, clomipramine, 40:91
- P300, electroencephalographic topography, 40:91
- P300, evoked potentials, 40:91
- P300, laterality, 40:91
- P300, serotonin, 40:91
- serotonin, clomipramine, 40:91
- serotonin, electroencephalographic topography, 40:91
- serotonin, evoked potentials, 40:91
- serotonin, laterality, 40:91
- serotonin, P300, 40:91

Fluphenazine

- magnetic resonance spectroscopy, pharmacokinetics, 35:107
- magnetic resonance spectroscopy, schizophrenia, 35:107
- pharmacokinetics, magnetic resonance spectroscopy, 35:107
- pharmacokinetics, schizophrenia, 35:107
- schizophrenia, magnetic resonance spectroscopy, 35:107
- schizophrenia, pharmacokinetics, 35:107

Frontal lobe

- affective disorder, Alzheimer's disease, 40:195
- affective disorder, glucose metabolism, 40:195
- affective disorder, hexamethylpropyleneamineoxime (HMPAO), 40:247
- affective disorder, hippocampus, 40:195
- affective disorder, limbic system, 40:247
- affective disorder, positron emission tomography, 40:195

Frontal lobe continued

- affective disorder, sleep, 40:247
- affective disorder, sleep deprivation, 40:247
- affective disorder, single photon emission computed tomography, 40:247
- Alzheimer's disease, affective disorder, 40:195
- Alzheimer's disease, glucose metabolism, 40:195
- Alzheimer's disease, hippocampus, 40:195
- Alzheimer's disease, positron emission tomography, 40:195
- anxiety, glucose metabolism, 35:49, 40:101
- anxiety, homovanillic acid, 40:101
- anxiety, laterality, 35:49
- anxiety, positron emission tomography, 35:49, 40:101
- anxiety, prolactin, 40:101
- anxiety, schizophrenia, 40:101
- anxiety, State-Trait Anxiety Inventory, 35:49
- apomorphine, glucose metabolism, 40:135
- apomorphine, never-medicated patients, 40:135
- apomorphine, positron emission tomography, 40:135
- apomorphine, schizophrenia, 40:135
- apomorphine, temporal lobe, 40:135
- basal ganglia, glucose, 40:115
- basal ganglia, neuroleptics, 40:115
- basal ganglia, positron emission tomography, 40:115
- basal ganglia, schizophrenia, 40:115
- blood flow, long-term followup, 40:253
- blood flow, schizophrenia, 35:27, 40:253
- blood flow, symptom severity, 35:27
- correlation analysis, glucose metabolism, 40:221
- correlation analysis, limbic system, 40:221
- correlation analysis, obsessive-compulsive disorder, 40:221
- correlation analysis, positron emission tomography, 40:221
- glucose, basal ganglia, 40:115
- glucose metabolism, affective disorder, 40:195
- glucose metabolism, Alzheimer's disease, 40:195
- glucose metabolism, anxiety, 35:49, 40:101
- glucose metabolism, apomorphine, 40:135
- glucose metabolism, correlation analysis, 40:221
- glucose metabolism, hippocampus, 40:195
- glucose metabolism, homovanillic acid, 40:101

Frontal lobe continued

glucose metabolism, laterality, 35:49
 glucose metabolism, limbic system, 40:221
 glucose metabolism, neuroleptics, 40:115
 glucose metabolism, never-medicated patients, 40:135
 glucose metabolism, obsessive-compulsive disorder, 40:221
 glucose metabolism, positron emission tomography, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
 glucose metabolism, prolactin, 40:101
 glucose metabolism, schizophrenia, 40:101, 40:115, 40:135
 glucose metabolism, State-Trait Anxiety Inventory, 35:49
 glucose metabolism, temporal lobe, 40:135
 hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
 hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
 hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
 hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
 hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
 hippocampus, affective disorder, 40:195
 hippocampus, Alzheimer's disease, 40:195
 hippocampus, glucose metabolism, 40:195
 hippocampus, positron emission tomography, 40:195
 homovanillic acid, anxiety, 40:101
 homovanillic acid, glucose metabolism, 40:101
 homovanillic acid, positron emission tomography, 40:101
 homovanillic acid, prolactin, 40:101
 homovanillic acid, schizophrenia, 40:101
 laterality, anxiety, 35:49
 laterality, glucose metabolism, 35:49
 laterality, positron emission tomography, 35:49
 laterality, State-Trait Anxiety Inventory, 35:49
 limbic system, affective disorder, 40:247
 limbic system, correlation analysis, 40:221
 limbic system, glucose metabolism, 40:221
 limbic system, hexamethylpropyleneamineoxime (HMPAO), 40:247
 limbic system, obsessive-compulsive disorder, 40:247
 limbic system, positron emission tomography, 40:247

Frontal lobe continued

limbic system, single photon emission computed tomography, 40:247
 limbic system, sleep, 40:247
 limbic system, sleep deprivation, 40:247
 long-term followup, blood flow, 40:253
 long-term followup, schizophrenia, 40:253
 neuroleptics, basal ganglia, 40:115
 neuroleptics, glucose, 40:115
 neuroleptics, positron emission tomography, 40:115
 neuroleptics, schizophrenia, 40:115
 never-medicated patients, apomorphine, 40:135
 never-medicated patients, glucose metabolism, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, schizophrenia, 40:135
 never-medicated patients, temporal lobe, 40:135
 obsessive-compulsive disorder, correlation analysis, 40:221
 obsessive-compulsive disorder, glucose metabolism, 40:221
 obsessive-compulsive disorder, limbic system, 40:221
 obsessive-compulsive disorder, positron emission tomography, 40:221
 positron emission tomography, affective disorder, 40:195
 positron emission tomography, Alzheimer's disease, 40:195
 positron emission tomography, anxiety, 35:49, 40:101
 positron emission tomography, apomorphine, 40:135
 positron emission tomography, basal ganglia, 40:115
 positron emission tomography, correlation analysis, 40:221
 positron emission tomography, glucose metabolism, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
 positron emission tomography, hippocampus, 40:195
 positron emission tomography, homovanillic acid, 40:101
 positron emission tomography, laterality, 35:49
 positron emission tomography, limbic system, 40:221
 positron emission tomography, neuroleptics, 40:115
 positron emission tomography, never-medicated patients, 40:135

Frontal lobe continued

positron emission tomography, obsessive-compulsive disorder, 40:221

positron emission tomography, prolactin, 40:101

positron emission tomography, schizophrenia, 40:101, 40:115, 40:135

positron emission tomography, State-Trait Anxiety Inventory, 35:49

positron emission tomography, temporal lobe, 40:135

prolactin, anxiety, 40:101

prolactin, glucose metabolism, 40:101

prolactin, homovanillic acid, 40:101

prolactin, positron emission tomography, 40:101

prolactin, schizophrenia, 40:101

schizophrenia, anxiety, 40:101

schizophrenia, apomorphine, 40:135

schizophrenia, basal ganglia, 40:115

schizophrenia, blood flow, 35:27, 40:253

schizophrenia, glucose metabolism, 40:101, 40:115, 40:135

schizophrenia, homovanillic acid, 40:101

schizophrenia, long-term followup, 40:253

schizophrenia, neuroleptics, 40:115

schizophrenia, never-medicated patients, 40:135

schizophrenia, positron emission tomography, 40:101, 40:115, 40:135

schizophrenia, prolactin, 40:101

schizophrenia, symptom severity, 35:27

schizophrenia, temporal lobe, 40:135

single photon emission computed tomography, affective disorder, 40:247

single photon emission computed tomography, hexamethylpropyleneamine-oxime (HMPAO), 40:247

single photon emission computed tomography, limbic system, 40:247

single photon emission computed tomography, sleep, 40:247

single photon emission computed tomography, sleep deprivation, 40:247

sleep, affective disorder, 40:247

sleep, hexamethylpropyleneamine-oxime (HMPAO), 40:247

sleep, limbic system, 40:247

sleep, single photon emission computed tomography, 40:247

sleep deprivation, affective disorder, 40:247

sleep deprivation, hexamethylpropyleneamine-oxime (HMPAO), 40:247

Frontal lobe continued

sleep deprivation, limbic system, 40:247

sleep deprivation, single photon emission computed tomography, 40:247

State-Trait Anxiety Inventory, anxiety, 35:49

State-Trait Anxiety Inventory, glucose metabolism, 35:49

State-Trait Anxiety Inventory, laterality, 35:49

State-Trait Anxiety Inventory, positron emission tomography, 35:49

symptom severity, blood flow, 35:27

symptom severity, schizophrenia, 35:27

temporal lobe, apomorphine, 40:135

temporal lobe, glucose metabolism, 40:135

temporal lobe, never-medicated patients, 40:135

temporal lobe, positron emission tomography, 40:135

temporal lobe, schizophrenia, 40:135

Gadolinium-DTPA

blood-brain barrier, cortical sulcal enlargement, 40:203

blood-brain barrier, magnetic resonance imaging, 40:203

blood-brain barrier, schizophrenia, 40:203

blood-brain barrier, ventricular size, 40:203

cortical sulcal enlargement, blood-brain barrier, 40:203

cortical sulcal enlargement, magnetic resonance imaging, 40:203

cortical sulcal enlargement, schizophrenia, 40:203

cortical sulcal enlargement, ventricular size, 40:203

magnetic resonance imaging, blood-brain barrier, 40:203

magnetic resonance imaging, cortical sulcal enlargement, 40:203

magnetic resonance imaging, schizophrenia, 40:203

magnetic resonance imaging, ventricular size, 40:203

schizophrenia, blood-brain barrier, 40:203

schizophrenia, cortical sulcal enlargement, 40:203

schizophrenia, magnetic resonance imaging, 40:203

schizophrenia, ventricular size, 40:203

ventricular size, blood-brain barrier, 40:203

ventricular size, cortical sulcal enlargement, 40:203

ventricular size, magnetic resonance imaging, 40:203

ventricular size, schizophrenia, 40:203

Gender

hippocampus, schizophrenia, 35:1
 schizophrenia, hippocampus, 35:1

Generalized anxiety disorder

blood flow, diazepam, 40:125
 blood flow, ondansetron, 40:125
 diazepam, blood flow, 40:125
 diazepam, ondansetron, 40:125
 ondansetron, blood flow, 40:125
 ondansetron, diazepam, 40:125

Genetics

admixture analysis, computed tomography, 35:61
 admixture analysis, schizophrenia, 35:61
 admixture analysis, ventricle-brain ratio, 35:61
 amygdala, hippocampus, 35:137
 amygdala, magnetic resonance imaging, 35:137
 amygdala, schizophrenia, 35:137
 amygdala, temporal lobe, 35:137
 amygdala, ventricular size, 35:137
 computed tomography, admixture analysis, 35:61
 computed tomography, schizophrenia, 35:61
 computed tomography, ventricle-brain ratio, 35:61
 cranial size, magnetic resonance imaging, 40:49
 cranial size, schizophrenia, 40:49
 cranial size, third ventricle, 40:49
 cranial size, ventricular size, 40:49
 hippocampus, amygdala, 35:137
 hippocampus, magnetic resonance imaging, 35:137
 hippocampus, schizophrenia, 35:137
 hippocampus, temporal lobe, 35:137
 hippocampus, ventricular size, 35:137
 magnetic resonance imaging, amygdala, 35:137
 magnetic resonance imaging, cranial size, 40:49
 magnetic resonance imaging, hippocampus, 35:137
 magnetic resonance imaging, schizophrenia, 35:137, 40:49
 magnetic resonance imaging, temporal lobe, 35:137
 magnetic resonance imaging, third ventricle, 40:49
 magnetic resonance imaging, ventricular size, 35:137, 40:49
 schizophrenia, admixture analysis, 35:61
 schizophrenia, amygdala, 35:137

Genetics continued

schizophrenia, computed tomography, 35:61
 schizophrenia, cranial size, 40:49
 schizophrenia, hippocampus, 35:137
 schizophrenia, magnetic resonance imaging, 35:137, 40:49
 schizophrenia, temporal lobe, 35:137
 schizophrenia, third ventricle, 40:49
 schizophrenia, ventricle-brain ratio, 35:61
 schizophrenia, ventricular size, 35:137, 40:49
 temporal lobe, amygdala, 35:137
 temporal lobe, hippocampus, 35:137
 temporal lobe, magnetic resonance imaging, 35:137
 temporal lobe, schizophrenia, 35:137
 temporal lobe, ventricular size, 35:137
 third ventricle, cranial size, 40:49
 third ventricle, magnetic resonance imaging, 40:49
 third ventricle, schizophrenia, 40:49
 third ventricle, ventricular size, 40:49
 ventricle-brain ratio, admixture analysis, 35:61
 ventricle-brain ratio, computed tomography, 35:61
 ventricle-brain ratio, schizophrenia, 35:61
 ventricular size, amygdala, 35:137
 ventricular size, cranial size, 40:49
 ventricular size, hippocampus, 35:137
 ventricular size, magnetic resonance imaging, 35:137, 40:49
 ventricular size, schizophrenia, 35:137, 40:49
 ventricular size, temporal lobe, 35:137
 ventricular size, third ventricle, 40:49

Glucose metabolism

affective disorder, Alzheimer's disease, 40:195
 affective disorder, frontal lobe, 40:195
 affective disorder, hippocampus, 40:195
 affective disorder, positron emission tomography, 40:195
 Alzheimer's disease, affective disorder, 40:195
 Alzheimer's disease, frontal lobe, 40:195
 Alzheimer's disease, hippocampus, 40:195
 Alzheimer's disease, positron emission tomography, 40:195
 anxiety, frontal lobe, 35:49, 40:101
 anxiety, homovanillic acid, 40:101
 anxiety, laterality, 35:49
 anxiety, positron emission tomography, 35:49, 40:101
 anxiety, prolactin, 40:101
 anxiety, schizophrenia, 40:101
 anxiety, State-Trait Anxiety Inventory, 35:49

Glucose metabolism continued

apomorphine, frontal lobe, 40:135
 apomorphine, never-medicated patients, 40:135
 apomorphine, positron emission tomography, 40:135
 apomorphine, schizophrenia, 40:135
 apomorphine, temporal lobe, 40:135
 basal ganglia, frontal lobe, 40:115
 basal ganglia, neuroleptics, 40:115
 basal ganglia, positron emission tomography, 40:115
 basal ganglia, schizophrenia, 40:115
 correlation analysis, frontal lobe, 40:221
 correlation analysis, limbic system, 40:221
 correlation analysis, obsessive-compulsive disorder, 40:221
 correlation analysis, positron emission tomography, 40:221
 ethanol, positron emission tomography, 35:39
 frontal lobe, affective disorder, 40:195
 frontal lobe, Alzheimer's disease, 40:195
 frontal lobe, anxiety, 35:49, 40:101
 frontal lobe, apomorphine, 40:135
 frontal lobe, basal ganglia, 40:115
 frontal lobe, correlation analysis, 40:221
 frontal lobe, hippocampus, 40:195
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, laterality, 35:49
 frontal lobe, limbic system, 40:221
 frontal lobe, neuroleptics, 40:115
 frontal lobe, never-medicated patients, 40:135
 frontal lobe, obsessive-compulsive disorder, 40:221
 frontal lobe, positron emission tomography, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
 frontal lobe, prolactin, 40:101
 frontal lobe, schizophrenia, 40:101, 40:115, 40:135
 frontal lobe, State-Trait Anxiety Inventory, 35:49
 frontal lobe, temporal lobe, 40:135
 hippocampus, affective disorder, 40:195
 hippocampus, Alzheimer's disease, 40:195
 hippocampus, frontal lobe, 40:195
 hippocampus, positron emission tomography, 40:195
 homovanillic acid, anxiety, 40:101
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, positron emission tomography, 40:101

Glucose metabolism, continued

homovanillic acid, prolactin, 40:101
 homovanillic acid, schizophrenia, 40:101
 laterality, anxiety, 35:49
 laterality, frontal lobe, 35:49
 laterality, positron emission tomography, 35:49
 laterality, State-Trait Anxiety Inventory, 35:49
 limbic system, correlation analysis, 40:221
 limbic system, frontal lobe, 40:221
 limbic system, obsessive-compulsive disorder, 40:221
 limbic system, positron emission tomography, 40:221
 measurement reliability, positron emission tomography, 40:11
 measurement reliability, relative vs. absolute metabolic rate, 40:11
 measurement reliability, schizophrenia, 40:11
 neuroleptics, basal ganglia, 40:115
 neuroleptics, frontal lobe, 40:115
 neuroleptics, positron emission tomography, 40:115
 neuroleptics, schizophrenia, 40:115
 never-medicated patients, apomorphine, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, schizophrenia, 40:135
 never-medicated patients, temporal lobe, 40:135
 obsessive-compulsive disorder, correlation analysis, 40:221
 obsessive-compulsive disorder, frontal lobe, 40:221
 obsessive-compulsive disorder, limbic system, 40:221
 obsessive-compulsive disorder, positron emission tomography, 40:221
 positron emission tomography, affective disorder, 40:195
 positron emission tomography, Alzheimer's disease, 40:195
 positron emission tomography, anxiety, 35:49, 40:101
 positron emission tomography, apomorphine, 40:135
 positron emission tomography, basal ganglia, 40:115

Glucose metabolism continued

- positron emission tomography, correlation analysis, 40:221
- positron emission tomography, ethanol, 35:39
- positron emission tomography, frontal lobe, 35:49, 40:101, 40:115, 40:195, 40:221
- positron emission tomography, hippocampus, 40:195
- positron emission tomography, homovanillic acid, 40:101
- positron emission tomography, laterality, 35:49
- positron emission tomography, limbic system, 40:221
- positron emission tomography, measurement reliability, 40:11
- positron emission tomography, neuroleptics, 40:115
- positron emission tomography, never-medicated patients, 40:135
- positron emission tomography, obsessive-compulsive disorder, 40:221
- positron emission tomography, prolactin, 40:101
- positron emission tomography, relative vs. absolute metabolic rate, 40:11
- positron emission tomography, schizophrenia, 40:11, 40:101, 40:115, 40:135
- positron emission tomography, State-Trait Anxiety Inventory, 35:49
- positron emission tomography, temporal lobe, 40:135
- positron emission tomography, tetrahydrocannabinol, 40:69
- prolactin, anxiety, 40:101
- prolactin, frontal lobe, 40:101
- prolactin, homovanillic acid, 40:101
- prolactin, positron emission tomography, 40:101
- prolactin, schizophrenia, 40:101
- relative vs. absolute metabolic rate, measurement reliability, 40:11
- relative vs. absolute metabolic rate, positron emission tomography, 40:11
- relative vs. absolute metabolic rate, schizophrenia, 40:11
- schizophrenia, anxiety, 40:101
- schizophrenia, apomorphine, 40:135
- schizophrenia, basal ganglia, 40:115
- schizophrenia, frontal lobe, 40:101, 40:115, 40:135
- schizophrenia, homovanillic acid, 40:101

Glucose metabolism continued

- schizophrenia, measurement reliability, 40:11
- schizophrenia, neuroleptics, 40:115
- schizophrenia, never-medicated patients, 40:135
- schizophrenia, positron emission tomography, 40:11, 40:101, 40:115, 40:135
- schizophrenia, prolactin, 40:101
- schizophrenia, relative vs. absolute metabolic rate, 40:11
- schizophrenia, temporal lobe, 40:135
- State-Trait Anxiety Inventory, anxiety, 35:49
- State-Trait Anxiety Inventory, frontal lobe, 35:49
- State-Trait Anxiety Inventory, laterality, 35:49
- State-Trait Anxiety Inventory, positron emission tomography, 35:49
- temporal lobe, apomorphine, 40:135
- temporal lobe, frontal lobe, 40:135
- temporal lobe, never-medicated patients, 40:135
- temporal lobe, positron emission tomography, 40:135
- temporal lobe, schizophrenia, 40:135
- tetrahydrocannabinol, positron emission tomography, 40:69
- Haloperidol**
- positron emission tomography, schizophrenia, 40:115
- schizophrenia, positron emission tomography, 40:115
- Hippocampus**
- affective disorder, Alzheimer's disease, 40:195
- affective disorder, frontal lobe, 40:195
- affective disorder, glucose metabolism, 40:195
- affective disorder, positron emission tomography, 40:195
- aging, limbic system, 35:15
- aging, magnetic resonance imaging, 35:15
- aging, ventricular size, 35:15
- Alzheimer's disease, affective disorder, 40:195
- Alzheimer's disease, astrocytosis, 35:149
- Alzheimer's disease, dentate gyrus, 35:149
- Alzheimer's disease, entorhinal cortex, 35:149
- Alzheimer's disease, frontal lobe, 40:195
- Alzheimer's disease, glucose metabolism, 40:195
- Alzheimer's disease, positron emission tomography, 40:195

Hippocampus continued

Alzheimer's disease, post-mortem examination, 35:149

Alzheimer's disease, schizophrenia, 35:149

amygdala, genetics, 35:137

amygdala, magnetic resonance imaging, 35:1, 35:137

amygdala, schizophrenia, 35:1, 35:137

amygdala, temporal horn volume, 35:1

amygdala, temporal lobe, 35:1, 35:137

amygdala, ventricular size, 35:137

astrocytosis, Alzheimer's disease, 35:149

astrocytosis, dentate gyrus, 35:149

astrocytosis, entorhinal cortex, 35:149

astrocytosis, post-mortem examination, 35:149

astrocytosis, schizophrenia, 35:149

dentate gyrus, Alzheimer's disease, 35:149

dentate gyrus, astrocytosis, 35:149

dentate gyrus, entorhinal cortex, 35:149

dentate gyrus, post-mortem examination, 35:149

dentate gyrus, schizophrenia, 35:149

entorhinal cortex, Alzheimer's disease, 35:149

entorhinal cortex, astrocytosis, 35:149

entorhinal cortex, dentate gyrus, 35:149

entorhinal cortex, post-mortem examination, 35:149

entorhinal cortex, schizophrenia, 35:149

frontal lobe, affective disorder, 40:195

frontal lobe, Alzheimer's disease, 40:195

frontal lobe, glucose metabolism, 40:195

frontal lobe, positron emission tomography, 40:195

gender, schizophrenia, 35:1

genetics, amygdala, 35:137

genetics, magnetic resonance imaging, 35:137

genetics, schizophrenia, 35:137

genetics, temporal lobe, 35:137

genetics, ventricular size, 35:137

glucose metabolism, affective disorder, 40:195

glucose metabolism, Alzheimer's disease, 40:195

glucose metabolism, frontal lobe, 40:195

glucose metabolism, positron emission tomography, 40:195

limbic system, aging, 35:15

limbic system, magnetic resonance imaging, 35:15

limbic system, ventricular size, 35:15

magnetic resonance imaging, aging, 35:15

Hippocampus continued

magnetic resonance imaging, amygdala, 35:1, 35:137

magnetic resonance imaging, genetics, 35:137

magnetic resonance imaging, limbic system, 35:15

magnetic resonance imaging, schizophrenia, 35:1, 35:137

magnetic resonance imaging, temporal horn volume, 35:1

magnetic resonance imaging, temporal lobe, 35:1, 35:137

magnetic resonance imaging, ventricular size, 35:15, 35:137

positron emission tomography, affective disorder, 40:195

positron emission tomography, Alzheimer's disease, 40:195

positron emission tomography, frontal lobe, 40:195

positron emission tomography, glucose metabolism, 40:195

post-mortem examination, Alzheimer's disease, 35:149

post-mortem examination, astrocytosis, 35:149

post-mortem examination, dentate gyrus, 35:149

post-mortem examination, entorhinal cortex, 35:149

post-mortem examination, schizophrenia, 35:149

schizophrenia, Alzheimer's disease, 35:149

schizophrenia, amygdala, 35:1, 35:137

schizophrenia, astrocytosis, 35:149

schizophrenia, dentate gyrus, 35:149

schizophrenia, entorhinal cortex, 35:149

schizophrenia, gender, 35:1

schizophrenia, genetics, 35:137

schizophrenia, magnetic resonance imaging, 35:1, 35:137

schizophrenia, post-mortem examination, 35:149

schizophrenia, temporal horn volume, 35:1

schizophrenia, temporal lobe, 35:1, 35:137

schizophrenia, ventricular size, 35:137

temporal horn volume, amygdala, 35:1

temporal horn volume, magnetic resonance imaging, 35:1

temporal horn volume, schizophrenia, 35:1

temporal horn volume, temporal lobe, 35:1

temporal lobe, amygdala, 35:1, 35:137

temporal lobe, genetics, 35:137

Hippocampus continued

temporal lobe, magnetic resonance imaging, 35:1, 35:137

temporal lobe, schizophrenia, 35:1, 35:137

temporal lobe, temporal horn volume, 35:1

temporal lobe, ventricular size, 35:137

ventricular size, aging, 35:15

ventricular size, amygdala, 35:137

ventricular size, genetics, 35:137

ventricular size, limbic system, 35:15

ventricular size, magnetic resonance imaging, 35:15, 35:137

ventricular size, schizophrenia, 35:137

ventricular size, temporal lobe, 35:137

HMPAO (Hexamethylpropyleneamine-oxime)

affective disorder, frontal lobe, 40:247

affective disorder, limbic system, 40:247

affective disorder, single photon emission computed tomography, 40:247

affective disorder, sleep, 40:247

affective disorder, sleep deprivation, 40:247

frontal lobe, affective disorder, 40:247

frontal lobe, limbic system, 40:247

frontal lobe, single photon emission computed tomography, 40:247

frontal lobe, sleep, 40:147

frontal lobe, sleep deprivation, 40:247

limbic system, affective disorder, 40:247

limbic system, frontal lobe, 40:247

limbic system, single photon emission computed tomography, 40:247

limbic system, sleep, 40:247

limbic system, sleep deprivation, 40:247

single photon emission computed tomography, affective disorder, 40:247

single photon emission computed tomography, frontal lobe, 40:247

single photon emission computed tomography, limbic system, 40:247

single photon emission computed tomography, sleep, 40:247

single photon emission computed tomography, sleep deprivation, 40:247

sleep, affective disorder, 40:247

sleep, frontal lobe, 40:247

sleep, limbic system, 40:247

sleep, single photon emission computed tomography, 40:247

sleep deprivation, affective disorder, 40:247

sleep deprivation, frontal lobe, 40:247

sleep deprivation, limbic system, 40:247

sleep deprivation, single photon emission computed tomography, 40:247

Homovanillic acid

anxiety, frontal lobe, 40:101

anxiety, glucose metabolism, 40:101

anxiety, positron emission tomography, 40:101

anxiety, prolactin, 40:101

anxiety, schizophrenia, 40:101

frontal lobe, anxiety, 40:101

frontal lobe, glucose metabolism, 40:101

frontal lobe, positron emission tomography, 40:101

frontal lobe, prolactin, 40:101

frontal lobe, schizophrenia, 40:101

glucose metabolism, anxiety, 40:101

glucose metabolism, frontal lobe, 40:101

glucose metabolism, positron emission tomography, 40:101

glucose metabolism, prolactin, 40:101

glucose metabolism, schizophrenia, 40:101

positron emission tomography, anxiety, 40:101

positron emission tomography, frontal lobe, 40:101

positron emission tomography, glucose metabolism, 40:101

positron emission tomography, prolactin, 40:101

positron emission tomography, schizophrenia, 40:101

prolactin, anxiety, 40:101

prolactin, frontal lobe, 40:101

prolactin, glucose metabolism, 40:101

prolactin, positron emission tomography, 40:101

prolactin, schizophrenia, 40:101

schizophrenia, anxiety, 40:101

schizophrenia, frontal lobe, 40:101

schizophrenia, glucose metabolism, 40:101

schizophrenia, positron emission tomography, 40:101

schizophrenia, prolactin, 40:101

Human immunodeficiency virus

brain size, magnetic resonance imaging, 40:61

magnetic resonance imaging, brain size, 40:61

Laterality

anxiety, frontal lobe, 35:49

anxiety, glucose metabolism, 35:49

anxiety, positron emission tomography, 35:49

anxiety, State-Trait Anxiety Inventory, 35:49

cerebral asymmetry, computed tomography, 35:71

Laterality continued

cerebral asymmetry, measurement methods, 35:71
 clomipramine, electroencephalographic topography, 40:91
 clomipramine, evoked potentials, 40:91
 clomipramine, fluoxetine, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 computed tomography, cerebral asymmetry, 35:71
 computed tomography, measurement methods, 35:71
 electroencephalographic topography, clomipramine, 40:91
 electroencephalographic topography, evoked potentials, 40:91
 electroencephalographic topography, fluoxetine, 40:91
 electroencephalographic topography, P300, 40:91
 electroencephalographic topography, serotonin, 40:91
 evoked potentials, clomipramine, 40:91
 evoked potentials, electroencephalographic topography, 40:91
 evoked potentials, fluoxetine, 40:91
 evoked potentials, P300, 40:91
 evoked potentials, serotonin, 40:91
 fluoxetine, clomipramine, 40:91
 fluoxetine, electroencephalographic topography, 40:91
 fluoxetine, evoked potentials, 40:91
 fluoxetine, P300, 40:91
 fluoxetine, serotonin, 40:91
 frontal lobe, anxiety, 35:49
 frontal lobe, glucose metabolism, 35:49
 frontal lobe, positron emission tomography, 35:49
 frontal lobe, State-Trait Anxiety Inventory, 35:49
 glucose metabolism, anxiety, 35:49
 glucose metabolism, frontal lobe, 35:49
 glucose metabolism, positron emission tomography, 35:49
 glucose metabolism, State-Trait Anxiety Inventory, 35:49
 measurement methods, cerebral asymmetry, 35:71
 measurement methods, computed tomography, 35:71
 P300, clomipramine, 40:91
 P300, electroencephalographic topography, 40:91
 P300, evoked potentials, 40:91

Laterality continued

P300, fluoxetine, 40:91
 P300, serotonin, 40:91
 positron emission tomography, anxiety, 35:49
 positron emission tomography, frontal lobe, 35:49
 positron emission tomography, glucose metabolism, 35:49
 positron emission tomography, State-Trait Anxiety Inventory, 35:49
 serotonin, clomipramine, 40:91
 serotonin, electroencephalographic topography, 40:91
 serotonin, evoked potentials, 40:91
 serotonin, fluoxetine, 40:91
 serotonin, P300, 40:91
 State-Trait Anxiety Inventory, anxiety, 35:49
 State-Trait Anxiety Inventory, frontal lobe, 35:49
 State-Trait Anxiety Inventory, glucose metabolism, 35:49
 State-Trait Anxiety Inventory, positron emission tomography, 35:49
Limbic system
 affective disorder, basal ganglia, 40:95
 affective disorder, frontal lobe, 40:247
 affective disorder, hexamethylpropyleneamineoxime (HMPAO), 40:247
 affective disorder, magnetic resonance imaging, 40:95
 affective disorder, putamen, 40:95
 affective disorder, single photon emission computed tomography, 40:247
 affective disorder, sleep, 40:247
 affective disorder, sleep deprivation, 40:247
 aging, hippocampus, 35:15
 aging, magnetic resonance imaging, 35:15
 aging, ventricular size, 35:15
 basal ganglia, affective disorder, 40:95
 basal ganglia, magnetic resonance imaging, 40:95
 basal ganglia, putamen, 40:95
 correlation analysis, frontal lobe, 40:221
 correlation analysis, glucose metabolism, 40:221
 correlation analysis, obsessive-compulsive disorder, 40:221
 correlation analysis, positron emission tomography, 40:221
 frontal lobe, affective disorder, 40:247
 frontal lobe, correlation analysis, 40:221
 frontal lobe, glucose metabolism, 40:221

Limbic system continued

- frontal lobe, hexamethylpropyleneamineoxime (HMPAO), 40:247
- frontal lobe, obsessive-compulsive disorder, 40:221
- frontal lobe, positron emission tomography, 40:221
- frontal lobe, single photon emission computed tomography, 40:247
- frontal lobe, sleep, 40:247
- frontal lobe, sleep deprivation, 40:247
- glucose metabolism, correlation analysis, 40:221
- glucose metabolism, frontal lobe, 40:221
- glucose metabolism, obsessive-compulsive disorder, 40:221
- glucose metabolism, positron emission tomography, 40:221
- hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
- hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
- hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
- hippocampus, aging, 35:15
- hippocampus, magnetic resonance imaging, 35:15
- hippocampus, ventricular size, 35:15
- magnetic resonance imaging, affective disorder, 40:95
- magnetic resonance imaging, aging, 35:15
- magnetic resonance imaging, basal ganglia, 40:95
- magnetic resonance imaging, hippocampus, 35:15
- magnetic resonance imaging, putamen, 40:95
- magnetic resonance imaging, ventricular size, 35:15
- obsessive-compulsive disorder, correlation analysis, 40:247
- obsessive-compulsive disorder, frontal lobe, 40:247
- obsessive-compulsive disorder, glucose metabolism, 40:247
- obsessive-compulsive disorder, positron emission tomography, 40:221
- positron emission tomography, correlation analysis, 40:221
- positron emission tomography, frontal lobe, 40:221

Limbic system continued

- positron emission tomography, glucose metabolism, 40:221
 - positron emission tomography, obsessive-compulsive disorder, 40:221
 - putamen, affective disorder, 40:95
 - putamen, basal ganglia, 40:95
 - putamen, magnetic resonance imaging, 40:95
 - single photon emission computed tomography, affective disorder, 40:247
 - single photon emission computed tomography, frontal lobe, 40:247
 - single photon emission computed tomography, hexamethylpropyleneamineoxime (HMPAO), 40:247
 - single photon emission computed tomography, sleep, 40:247
 - single photon emission computed tomography, sleep deprivation, 40:247
 - sleep, affective disorder, 40:247
 - sleep deprivation, affective disorder, 40:247
 - sleep deprivation, frontal lobe, 40:247
 - sleep deprivation, hexamethylpropyleneamineoxime (HMPAO), 40:247
 - sleep deprivation, single photon emission computed tomography, 40:247
 - sleep, frontal lobe, 40:247
 - sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
 - sleep, single photon emission computed tomography, 40:247
 - ventricular size, aging, 35:15
 - ventricular size, hippocampus, 35:15
 - ventricular size, magnetic resonance imaging, 35:15
- Locus ceruleus**
- brain stem reticular formation, neuropathology, 40:31
 - brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
 - brain stem reticular formation, pedunculopontine nucleus, 40:31
 - brain stem reticular formation, schizophrenia, 40:31
 - neuropathology, brain stem reticular formation, 40:31
 - neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
 - neuropathology, pedunculopontine nucleus, 40:31
 - neuropathology, schizophrenia, 40:31
 - nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31

Locus ceruleus continued

- nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
- nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
- nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
- pedunculopontine nucleus, brain stem reticular formation, 40:31
- pedunculopontine nucleus, neuropathology, 40:31
- pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
- pedunculopontine nucleus, schizophrenia, 40:31
- schizophrenia, brain stem reticular formation, 40:31
- schizophrenia, neuropathology, 40:31
- schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
- schizophrenia, pedunculopontine nucleus, 40:31

Magnetic resonance imaging

- affective disorder, aging, 40:211
- affective disorder, basal ganglia, 40:95
- affective disorder, late onset, 40:211
- affective disorder, limbic system, 40:95
- affective disorder, mania, 40:211
- affective disorder, putamen, 40:95
- affective disorder, subcortical hyperintensities, 40:211
- aging, affective disorder, 40:211
- aging, hippocampus, 35:15
- aging, late onset, 40:211
- aging, limbic system, 35:15
- aging, mania, 40:211
- aging, subcortical hyperintensities, 40:211
- aging, ventricular size, 35:15
- amygdala, genetics, 35:137
- amygdala, hippocampus, 35:1, 35:137
- amygdala, schizophrenia, 35:1, 35:137
- amygdala, temporal horn volume, 35:1
- amygdala, temporal lobe, 35:1, 35:137
- amygdala, ventricular size, 35:137
- basal ganglia, affective disorder, 40:95
- basal ganglia, limbic system, 40:95
- basal ganglia, putamen, 40:95
- basal ganglia, schizophrenia, 40:157
- basal ganglia, tardive dyskinesia, 40:157
- blood-brain barrier, cortical sulcal enlargement, 40:203
- blood-brain barrier, gadolinium-DPTA, 40:203

Magnetic resonance imaging continued

- blood-brain barrier, schizophrenia, 40:203
- blood-brain barrier, ventricular size, 40:203
- brain volume, computer methods, 40:61
- computer methods, brain volume, 40:61
- cortical sulcal enlargement, blood-brain barrier, 40:203
- cortical sulcal enlargement, gadolinium-DPTA, 40:203
- cortical sulcal enlargement, schizophrenia, 40:203
- cortical sulcal enlargement, ventricular size, 40:203
- cranial size, genetics, 40:49
- cranial size, schizophrenia, 40:49
- cranial size, third ventricle, 40:49
- cranial size, ventricular size, 40:49
- fluorinated neuroleptics, spectroscopy, 35:107
- fluphenazine, pharmacokinetics, 35:107
- fluphenazine, schizophrenia, 35:107
- gadolinium-DPTA, blood-brain barrier, 40:203
- gadolinium-DPTA, cortical sulcal enlargement, 40:203
- gadolinium-DPTA, schizophrenia, 40:203
- gadolinium-DPTA, ventricular size, 40:203
- genetics, amygdala, 35:137
- genetics, cranial size, 40:49
- genetics, hippocampus, 35:137
- genetics, schizophrenia, 35:137, 40:49
- genetics, temporal lobe, 35:137
- genetics, third ventricle, 40:49
- genetics, ventricular size, 35:137, 40:49
- hippocampus, aging, 35:15
- hippocampus, amygdala, 35:1, 35:137
- hippocampus, genetics, 35:137
- hippocampus, limbic system, 35:15
- hippocampus, schizophrenia, 35:1, 35:137
- hippocampus, temporal horn volume, 35:1
- hippocampus, temporal lobe, 35:1, 35:137
- hippocampus, ventricular size, 35:15, 35:137
- late onset, affective disorder, 40:211
- late onset, aging, 40:211
- late onset, mania, 40:211
- late onset, subcortical hyperintensities, 40:211
- limbic system, affective disorder, 40:95
- limbic system, aging, 35:15
- limbic system, basal ganglia, 40:95
- limbic system, hippocampus, 35:15
- limbic system, putamen, 40:95
- limbic system, ventricular size, 35:15
- mania, aging, 40:211

Magnetic resonance imaging continued

mania, late onset, 40:211
 mania, subcortical hyperintensities, 40:wm
 pharmacokinetics, fluphenazine, 35:107
 pharmacokinetics, schizophrenia, 35:107
 putamen, affective disorder, 40:95
 putamen, basal ganglia, 40:95
 putamen, limbic system, 40:95
 ratio measurement reliability, ventricle-brain ratio, 40:79
 schizophrenia, amygdala, 35:1, 35:137
 schizophrenia, basal ganglia, 40:157
 schizophrenia, blood-brain barrier, 40:203
 schizophrenia, cortical sulcal enlargement, 40:203
 schizophrenia, cranial size, 40:49
 schizophrenia, fluphenazine, 35:107
 schizophrenia, gadolinium-DPTA, 40:203
 schizophrenia, genetics, 35:137, 40:49
 schizophrenia, hippocampus, 35:1, 35:137
 schizophrenia, pharmacokinetics, 35:107
 schizophrenia, T2 hyperintense foci, 40:239
 schizophrenia, tardive dyskinesia, 40:157, 40:239
 schizophrenia, temporal horn volume, 35:1
 schizophrenia, temporal lobe, 35:1, 35:137
 schizophrenia, third ventricle, 40:49
 schizophrenia, ventricular size, 35:137, 40:49, 40:203
 spectroscopy, fluorinated neuroleptics, 35:107
 subcortical hyperintensities, affective disorder, 40:211
 subcortical hyperintensities, aging, 40:211
 subcortical hyperintensities, late onset, 40:211
 subcortical hyperintensities, mania, 40:211
 T2 hyperintense foci, schizophrenia, 40:239
 T2 hyperintense foci, tardive dyskinesia, 40:239
 tardive dyskinesia, basal ganglia, 40:157
 tardive dyskinesia, schizophrenia, 40:157, 40:239
 tardive dyskinesia, T2 hyperintense foci, 40:239
 temporal horn volume, amygdala, 35:1
 temporal horn volume, hippocampus, 35:1
 temporal horn volume, schizophrenia, 35:1
 temporal horn volume, temporal lobe, 35:1
 temporal lobe, amygdala, 35:1, 35:137
 temporal lobe, genetics, 35:137
 temporal lobe, hippocampus, 35:1, 35:137
 temporal lobe, schizophrenia, 35:1, 35:137
 temporal lobe, temporal horn volume, 35:1

Magnetic resonance imaging continued

temporal lobe, ventricular size, 35:137
 third ventricle, cranial size, 40:49
 third ventricle, genetics, 40:49
 third ventricle, schizophrenia, 40:49
 third ventricle, ventricular size, 40:49
 ventricle-brain ratio, ratio measurement reliability, 40:79
 ventricular size, aging, 35:15
 ventricular size, amygdala, 35:137
 ventricular size, blood-brain barrier, 40:203
 ventricular size, cortical sulcal enlargement, 40:203
 ventricular size, cranial size, 40:49
 ventricular size, gadolinium-DPTA, 40:203
 ventricular size, genetics, 35:137, 40:49
 ventricular size, hippocampus, 35:137, 35:15
 ventricular size, limbic system, 35:15
 ventricular size, schizophrenia, 35:137, 40:49, 40:203
 ventricular size, temporal lobe, 35:137
 ventricular size, third ventricle, 40:49

Neuroleptics

basal ganglia, frontal lobe, 40:115
 basal ganglia, glucose, 40:115
 basal ganglia, positron emission tomography, 40:115
 basal ganglia, schizophrenia, 40:115
 frontal lobe, basal ganglia, 40:115
 frontal lobe, glucose, 40:115
 frontal lobe, positron emission tomography, 40:115
 frontal lobe, schizophrenia, 40:115
 glucose, basal ganglia, 40:115
 glucose, frontal lobe, 40:115
 glucose, positron emission tomography, 40:115
 glucose, schizophrenia, 40:115
 positron emission tomography, basal ganglia, 40:115
 positron emission tomography, frontal lobe, 40:115
 positron emission tomography, glucose, 40:115
 positron emission tomography, schizophrenia, 40:115
 schizophrenia, basal ganglia, 40:115
 schizophrenia, frontal lobe, 40:115
 schizophrenia, glucose, 40:115
 schizophrenia, positron emission tomography, 40:115

Neuropathology

Alzheimer's disease, astrocytosis, 35:149
 Alzheimer's disease, schizophrenia, 35:149

Neuropathology continued

- astrocytosis, Alzheimer's disease, 35:149
- astrocytosis, schizophrenia, 35:149
- brain stem reticular formation, locus ceruleus, 40:31
- brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
- brain stem reticular formation, pedunculo pontine nucleus, 40:31
- brain stem reticular formation, schizophrenia, 40:31
- locus ceruleus, brain stem reticular formation, 40:31
- locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
- locus ceruleus, pedunculo pontine nucleus, 40:31
- locus ceruleus, schizophrenia, 40:31
- nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
- nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
- nicotinamide adenosine dinucleotide phosphate, pedunculo pontine nucleus, 40:31
- nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
- pedunculo pontine nucleus, brain stem reticular formation, 40:31
- pedunculo pontine nucleus, locus ceruleus, 40:31
- pedunculo pontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
- pedunculo pontine nucleus, schizophrenia, 40:31
- schizophrenia, Alzheimer's disease, 35:149
- schizophrenia, astrocytosis, 35:149
- schizophrenia, brain stem reticular formation, 40:31
- schizophrenia, locus ceruleus, 40:31
- schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
- schizophrenia, pedunculo pontine nucleus, 40:31

Neuropsychology

- Alzheimer's disease, computed tomography, 35:115
- Alzheimer's disease, electroencephalographic topography, 40:181
- Alzheimer's disease, severity of dementia, 40:181
- blood flow, Chicago Word Fluency Test, 40:253

Neuropsychology continued

- blood flow, schizophrenia, 40:253
- blood flow, Wisconsin Card Sort Test, 40:253
- Chicago Word Fluency Test, blood flow, 40:253
- computed tomography, Alzheimer's disease, 35:115
- electroencephalographic topography, Alzheimer's disease, 40:181
- electroencephalographic topography, severity of dementia, 40:181
- schizophrenia, blood flow, 40:253
- schizophrenia, Wisconsin Card Sort Test, 40:253
- severity of dementia, Alzheimer's disease, 40:181
- severity of dementia, electroencephalographic topography, 40:181
- Wisconsin Card Sort Test, blood flow, 40:253
- Wisconsin Card Sort Test, schizophrenia, 40:253
- Nicotinamide adenosine dinucleotide phosphate-diaphorase histochemistry**
- brain stem reticular formation, locus ceruleus, 40:31
- brain stem reticular formation, neuropathology, 40:31
- brain stem reticular formation, pedunculo pontine nucleus, 40:31
- brain stem reticular formation, schizophrenia, 40:31
- locus ceruleus, brain stem reticular formation, 40:31
- locus ceruleus, neuropathology, 40:31
- locus ceruleus, pedunculo pontine nucleus, 40:31
- locus ceruleus, schizophrenia, 40:31
- neuropathology, brain stem reticular formation, 40:31
- neuropathology, locus ceruleus, 40:31
- neuropathology, pedunculo pontine nucleus, 40:31
- neuropathology, schizophrenia, 40:31
- pedunculo pontine nucleus, brain stem reticular formation, 40:31
- pedunculo pontine nucleus, locus ceruleus, 40:31
- pedunculo pontine nucleus, neuropathology, 40:31
- pedunculo pontine nucleus, schizophrenia, 40:31
- post-mortem, schizophrenia, 40:31

Nicotinamide adenosine dinucleotide phosphate-diaphorase histochemistry continued
schizophrenia, brain stem reticular formation, 40:31

schizophrenia, locus ceruleus, 40:31
schizophrenia, neuropathology, 40:31
schizophrenia, pedunculopontine nucleus, 40:31

schizophrenia, post-mortem, 40:31

Obsessive-compulsive disorder

brain size, magnetic resonance imaging, 40:61

correlation analysis, frontal lobe, 40:221

correlation analysis, glucose metabolism, 40:221

correlation analysis, limbic system, 40:221

correlation analysis, positron emission tomography, 40:221

frontal lobe, correlation analysis, 40:221

frontal lobe, glucose metabolism, 40:221

frontal lobe, limbic system, 40:221

frontal lobe, positron emission tomography, 40:221

glucose metabolism, correlation analysis, 40:221

glucose metabolism, frontal lobe, 40:221

glucose metabolism, limbic system, 40:221

glucose metabolism, positron emission tomography, 40:221

limbic system, correlation analysis, 40:221

limbic system, frontal lobe, 40:221

limbic system, glucose metabolism, 40:221

limbic system, positron emission tomography, 40:221

magnetic resonance imaging, brain size, 40:61

positron emission tomography, correlation analysis, 40:221

positron emission tomography, frontal lobe, 40:221

positron emission tomography, glucose metabolism, 40:221

positron emission tomography, limbic system, 40:221

Ondansetron

anxiety, blood flow, 40:125

anxiety, diazepam, 40:125

anxiety, generalized anxiety disorder, 40:125

blood flow, anxiety, 40:125

blood flow, diazepam, 40:125

blood flow, generalized anxiety disorder, 40:125

diazepam, anxiety, 40:125

diazepam, blood flow, 40:125

diazepam, generalized anxiety disorder, 40:125

generalized anxiety disorder, anxiety, 40:125

Ondansetron continued

generalized anxiety disorder, blood flow, 40:125

generalized anxiety disorder, diazepam, 40:125

Pedunculopontine nucleus

brain stem reticular formation, locus ceruleus, 40:31

brain stem reticular formation, neuropathology, 40:31

brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31

brain stem reticular formation, schizophrenia, 40:31

locus ceruleus, brain stem reticular formation, 40:31

locus ceruleus, neuropathology, 40:31

locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31

locus ceruleus, schizophrenia, 40:31

neuropathology, brain stem reticular formation, 40:31

neuropathology, locus ceruleus, 40:31

neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31

neuropathology, schizophrenia, 40:31

nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31

nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31

nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31

nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31

schizophrenia, brain stem reticular formation, 40:31

schizophrenia, locus ceruleus, 40:31

schizophrenia, neuropathology, 40:31

schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31

Polysomnography

arecoline, electroencephalographic topography, 35:91

arecoline, sleep, 35:91

electroencephalographic topography, arecoline, 35:91

electroencephalographic topography, sleep, 35:91

sleep, arecoline, 35:91

sleep, electroencephalographic topography, 35:91

Positron emission tomography

affective disorder, Alzheimer's disease, 40:195

Positron emission tomography continued

affective disorder, frontal lobe, 40:195
 affective disorder, glucose metabolism, 40:195
 affective disorder, hippocampus, 40:195
 Alzheimer's disease, affective disorder, 40:195
 Alzheimer's disease, frontal lobe, 40:195
 Alzheimer's disease, glucose metabolism, 40:195
 Alzheimer's disease, hippocampus, 40:195
 anxiety, frontal lobe, 35:49, 40:101
 anxiety, glucose metabolism, 35:49, 40:101
 anxiety, homovanillic acid, 40:101
 anxiety, laterality, 35:49
 anxiety, prolactin, 40:101
 anxiety, schizophrenia, 40:101
 anxiety, State-Trait Anxiety Inventory, 35:49
 apomorphine, frontal lobe, 40:135
 apomorphine, glucose metabolism, 40:135
 apomorphine, never-medicated patients, 40:135
 apomorphine, schizophrenia, 40:135
 apomorphine, temporal lobe, 40:135
 basal ganglia, glucose, 40:115
 basal ganglia, neuroleptics, 40:115
 basal ganglia, schizophrenia, 40:115
 correlation analysis, frontal lobe, 40:221
 correlation analysis, glucose metabolism, 40:221
 correlation analysis, limbic system, 40:221
 correlation analysis, obsessive-compulsive disorder, 40:221
 ethanol, glucose metabolism, 35:39
 frontal lobe, affective disorder, 40:195
 frontal lobe, Alzheimer's disease, 40:195
 frontal lobe, anxiety, 35:49, 40:101
 frontal lobe, apomorphine, 40:135
 frontal lobe, basal ganglia, 40:115
 frontal lobe, correlation analysis, 40:221
 frontal lobe, glucose, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, laterality, 35:49
 frontal lobe, limbic system, 40:221
 frontal lobe, neuroleptics, 40:115
 frontal lobe, never-medicated patients, 40:135
 frontal lobe, obsessive-compulsive disorder, 40:221
 frontal lobe, prolactin, 40:101
 frontal lobe, schizophrenia, 40:101, 40:115, 40:135

Positron emission tomography continued

frontal lobe, State-Trait Anxiety Inventory, 35:49
 glucose, basal ganglia, 40:115
 glucose, frontal lobe, 40:115
 glucose metabolism, affective disorder, 40:195
 glucose metabolism, Alzheimer's disease, 40:195
 glucose metabolism, anxiety, 35:49, 40:101
 glucose metabolism, apomorphine, 40:135
 glucose metabolism, correlation analysis, 40:221
 glucose metabolism, ethanol, 35:39
 glucose metabolism, frontal lobe, 35:49, 40:101, 40:135, 40:195, 40:221
 glucose metabolism, hippocampus, 40:195
 glucose metabolism, homovanillic acid, 40:101
 glucose metabolism, laterality, 35:49
 glucose metabolism, limbic system, 40:221
 glucose metabolism, measurement reliability, 40:11
 glucose metabolism, never-medicated patients, 40:135
 glucose metabolism, obsessive-compulsive disorder, 40:221
 glucose metabolism, prolactin, 40:101
 glucose metabolism, relative vs. absolute metabolic rate, 40:11
 glucose metabolism, schizophrenia, 40:11, 40:101, 40:135
 glucose metabolism, State-Trait Anxiety Inventory, 35:49
 glucose metabolism, temporal lobe, 40:135
 glucose metabolism, tetrahydrocannabinol, 40:69
 glucose, neuroleptics, 40:115
 glucose, schizophrenia, 40:115
 haloperidol, schizophrenia, 40:115
 hippocampus, affective disorder, 40:195
 hippocampus, Alzheimer's disease, 40:195
 hippocampus, frontal lobe, 40:195
 hippocampus, glucose metabolism, 40:195
 homovanillic acid, anxiety, 40:101
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, glucose metabolism, 40:101
 homovanillic acid, prolactin, 40:101
 homovanillic acid, schizophrenia, 40:101
 laterality, anxiety, 35:49
 laterality, frontal lobe, 35:49
 laterality, glucose metabolism, 35:49
 laterality, State-Trait Anxiety Inventory, 35:49

Positron emission tomography continued

- limbic system, correlation analysis, 40:221
- limbic system, frontal lobe, 40:221
- limbic system, glucose metabolism, 40:221
- limbic system, obsessive-compulsive disorder, 40:221
- measurement reliability, glucose metabolism, 40:11
- measurement reliability, relative vs. absolute metabolic rate, 40:11
- measurement reliability, schizophrenia, 40:11
- neuroleptics, basal ganglia, 40:115
- neuroleptics, frontal lobe, 40:115
- neuroleptics, glucose, 40:115
- neuroleptics, schizophrenia, 40:115
- never-medicated patients, apomorphine, 40:135
- never-medicated patients, frontal lobe, 40:135
- never-medicated patients, glucose metabolism, 40:135
- never-medicated patients, schizophrenia, 40:135
- never-medicated patients, temporal lobe, 40:135
- obsessive-compulsive disorder, correlation analysis, 40:221
- obsessive-compulsive disorder, frontal lobe, 40:221
- obsessive-compulsive disorder, glucose metabolism, 40:221
- obsessive-compulsive disorder, limbic system, 40:221
- prolactin, anxiety, 40:101
- prolactin, frontal lobe, 40:101
- prolactin, glucose metabolism, 40:101
- prolactin, homovanillic acid, 40:101
- prolactin, schizophrenia, 40:101
- relative vs. absolute metabolic rate, glucose metabolism, 40:11
- relative vs. absolute metabolic rate, measurement reliability, 40:11
- relative vs. absolute metabolic rate, schizophrenia, 40:11
- schizophrenia, anxiety, 40:101
- schizophrenia, apomorphine, 40:135
- schizophrenia, basal ganglia, 40:115
- schizophrenia, frontal lobe, 40:101, 40:115, 40:135
- schizophrenia, glucose metabolism, 40:11, 40:101, 40:135
- schizophrenia, haloperidol, 40:115
- schizophrenia, homovanillic acid, 40:101

Positron emission tomography continued

- schizophrenia, measurement reliability, 40:11
- schizophrenia, neuroleptics, 40:115
- schizophrenia, never-medicated patients, 40:135
- schizophrenia, prolactin, 40:101
- schizophrenia, relative vs. absolute metabolic rate, 40:11
- schizophrenia, temporal lobe, 40:135
- schizophrenia, thiothixene, 40:115
- State-Trait Anxiety Inventory, anxiety, 35:49
- State-Trait Anxiety Inventory, frontal lobe, 35:49
- State-Trait Anxiety Inventory, glucose metabolism, 35:49
- State-Trait Anxiety Inventory, laterality, 35:49
- temporal lobe, apomorphine, 40:135
- temporal lobe, frontal lobe, 40:135
- temporal lobe, glucose metabolism, 40:135
- temporal lobe, never-medicated patients, 40:135
- temporal lobe, schizophrenia, 40:135
- tetrahydrocannabinol, glucose metabolism, 40:69
- thiothixene, schizophrenia, 40:115
- Post-mortem studies.** See also Neuro-pathology
- nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
- schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
- Prolactin**
- anxiety, frontal lobe, 40:101
- anxiety, glucose metabolism, 40:101
- anxiety, homovanillic acid, 40:101
- anxiety, positron emission tomography, 40:101
- anxiety, schizophrenia, 40:101
- frontal lobe, anxiety, 40:101
- frontal lobe, glucose metabolism, 40:101
- frontal lobe, homovanillic acid, 40:101
- frontal lobe, positron emission tomography, 40:101
- frontal lobe, schizophrenia, 40:101
- glucose metabolism, anxiety, 40:101
- glucose metabolism, frontal lobe, 40:101
- glucose metabolism, homovanillic acid, 40:101
- glucose metabolism, positron emission tomography, 40:101
- glucose metabolism, schizophrenia, 40:101

Prolactin continued

- homovanillic acid, anxiety, 40:101
- homovanillic acid, frontal lobe, 40:101
- homovanillic acid, glucose metabolism, 40:101
- homovanillic acid, positron emission tomography, 40:101
- homovanillic acid, schizophrenia, 40:101
- positron emission tomography, anxiety, 40:101
- positron emission tomography, frontal lobe, 40:101
- positron emission tomography, glucose metabolism, 40:101
- positron emission tomography, homovanillic acid, 40:101
- positron emission tomography, schizophrenia, 40:101
- schizophrenia, anxiety, 40:101
- schizophrenia, frontal lobe, 40:101
- schizophrenia, glucose metabolism, 40:101
- schizophrenia, homovanillic acid, 40:101
- schizophrenia, positron emission tomography, 40:101

Schizophrenia

- admixture analysis, computed tomography, 35:61
- admixture analysis, genetics, 35:61
- admixture analysis, ventricle-brain ratio, 35:61
- Alzheimer's disease, astrocytosis, 35:149
- Alzheimer's disease, dentate gyrus, 35:149
- Alzheimer's disease, entorhinal cortex, 35:149
- Alzheimer's disease, hippocampus, 35:149
- Alzheimer's disease, post-mortem examination, 35:149
- amygdala, genetics, 35:137
- amygdala, hippocampus, 35:1, 35:137
- amygdala, magnetic resonance imaging, 35:1, 35:137
- amygdala, temporal horn volume, 35:1
- amygdala, temporal lobe, 35:1, 35:137
- amygdala, ventricular size, 35:137
- anxiety, frontal lobe, 40:101
- anxiety, glucose metabolism, 40:101
- anxiety, homovanillic acid, 40:101
- anxiety, positron emission tomography, 40:101
- anxiety, prolactin, 40:101
- apomorphine, frontal lobe, 40:135
- apomorphine, glucose metabolism, 40:135
- apomorphine, never-medicated patients, 40:135

Schizophrenia continued

- apomorphine, positron emission tomography, 40:135
- apomorphine, temporal lobe, 40:135
- astrocytosis, Alzheimer's disease, 35:149
- astrocytosis, dentate gyrus, 35:149
- astrocytosis, entorhinal cortex, 35:149
- astrocytosis, hippocampus, 35:149
- astrocytosis, post-mortem examination, 35:149
- basal ganglia, frontal lobe, 40:115
- basal ganglia, glucose, 40:115
- basal ganglia, magnetic resonance imaging, 40:157
- basal ganglia, neuroleptics, 40:115
- basal ganglia, positron emission tomography, 40:115
- basal ganglia, tardive dyskinesia, 40:157
- blood-brain barrier, cortical sulcal enlargement, 40:203
- blood-brain barrier, gadolinium-DPTA, 40:203
- blood-brain barrier, magnetic resonance imaging, 40:203
- blood-brain barrier, ventricular size, 40:203
- blood flow, frontal lobe, 35:27, 40:253
- blood flow, long-term followup, 40:253
- blood flow, neuropsychology, 40:253
- blood flow, symptom severity, 35:27
- blood flow, Wisconsin Card Sort Test, 40:253
- brain size, magnetic resonance imaging, 40:61
- brain stem reticular formation, locus ceruleus, 40:31
- brain stem reticular formation, neuropathology, 40:31
- brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
- brain stem reticular formation, pedunculopontine nucleus, 40:31
- computed tomography, admixture analysis, 35:61
- computed tomography, genetics, 35:61
- computed tomography, stability after psychosis onset, 40:21
- computed tomography, ventricle-brain ratio, 35:61
- computed tomography, ventricular size, 40:21
- cortical sulcal enlargement, blood-brain barrier, 40:203
- cortical sulcal enlargement, gadolinium-DPTA, 40:203

Schizophrenia continued

cortical sulcal enlargement, magnetic resonance imaging, 40:203
 cortical sulcal enlargement, ventricular size, 40:203
 cranial size, genetics, 40:49
 cranial size, magnetic resonance imaging, 40:49
 cranial size, third ventricle, 40:49
 cranial size, ventricular size, 40:49
 dentate gyrus, Alzheimer's disease, 35:149
 dentate gyrus, astrocytosis, 35:149
 dentate gyrus, entorhinal cortex, 35:149
 dentate gyrus, hippocampus, 35:149
 dentate gyrus, post-mortem examination, 35:149
 entorhinal cortex, Alzheimer's disease, 35:149
 entorhinal cortex, astrocytosis, 35:149
 entorhinal cortex, dentate gyrus, 35:149
 entorhinal cortex, hippocampus, 35:149
 entorhinal cortex, post-mortem examination, 35:149
 fluphenazine, magnetic resonance spectroscopy, 35:107
 fluphenazine, pharmacokinetics, 35:107
 frontal lobe, anxiety, 40:101
 frontal lobe, apomorphine, 40:135
 frontal lobe, basal ganglia, 40:115
 frontal lobe, blood flow, 35:27, 40:253
 frontal lobe, glucose, 40:115
 frontal lobe, glucose metabolism, 40:101, 40:135
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, long-term followup, 40:253
 frontal lobe, neuroleptics, 40:115
 frontal lobe, never-medicated patients, 40:135
 frontal lobe, positron emission tomography, 40:101, 40:115, 40:135
 frontal lobe, prolactin, 40:101
 frontal lobe, symptom severity, 35:27
 frontal lobe, temporal lobe, 40:135
 gadolinium-DPTA, blood-brain barrier, 40:203
 gadolinium-DPTA, cortical sulcal enlargement, 40:203
 gadolinium-DPTA, magnetic resonance imaging, 40:203
 gadolinium-DPTA, ventricular size, 40:203
 gender, hippocampus, 35:1
 genetics, admixture analysis, 35:61
 genetics, amygdala, 35:137
 genetics, computed tomography, 35:61

Schizophrenia continued

genetics, cranial size, 40:49
 genetics, hippocampus, 35:137
 genetics, magnetic resonance imaging, 35:137, 40:49
 genetics, temporal lobe, 35:137
 genetics, third ventricle, 40:49
 genetics, ventricle-brain ratio, 35:61
 genetics, ventricular size, 35:137, 40:49
 glucose, basal ganglia, 40:115
 glucose, frontal lobe, 40:115
 glucose metabolism, anxiety, 40:101
 glucose metabolism, apomorphine, 40:135
 glucose metabolism, frontal lobe, 40:101, 40:135
 glucose metabolism, homovanillic acid, 40:101
 glucose metabolism, measurement reliability, 40:11
 glucose metabolism, never-medicated patients, 40:135
 glucose metabolism, positron emission tomography, 40:11, 40:101, 40:135
 glucose metabolism, prolactin, 40:101
 glucose metabolism, relative vs. absolute metabolic rate, 40:11
 glucose metabolism, temporal lobe, 40:135
 glucose, neuroleptics, 40:115
 glucose, positron emission tomography, 40:115
 haloperidol, positron emission tomography, 40:115
 hippocampus, Alzheimer's disease, 35:149
 hippocampus, amygdala, 35:1, 35:137
 hippocampus, astrocytosis, 35:149
 hippocampus, dentate gyrus, 35:149
 hippocampus, entorhinal cortex, 35:149
 hippocampus, gender, 35:1
 hippocampus, genetics, 35:137
 hippocampus, magnetic resonance imaging, 35:1, 35:137
 hippocampus, post-mortem examination, 35:149
 hippocampus, temporal horn volume, 35:1
 hippocampus, temporal lobe, 35:1, 35:137
 hippocampus, ventricular size, 35:137
 homovanillic acid, anxiety, 40:101
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, glucose metabolism, 40:101
 homovanillic acid, positron emission tomography, 40:101
 homovanillic acid, prolactin, 40:101
 locus ceruleus, brain stem reticular formation, 40:31

Schizophrenia continued

locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 locus ceruleus, neuropathology, 40:31
 locus ceruleus, pedunculopontine nucleus, 40:31
 long-term followup, blood flow, 40:253
 long-term followup, frontal lobe, 40:253
 magnetic resonance imaging, amygdala, 35:1, 35:137
 magnetic resonance imaging, basal ganglia, 40:157
 magnetic resonance imaging, blood-brain barrier, 40:203
 magnetic resonance imaging, brain size, 40:61
 magnetic resonance imaging, cortical sulcal enlargement, 40:203
 magnetic resonance imaging, cranial size, 40:49
 magnetic resonance imaging, gadolinium-DPTA, 40:203
 magnetic resonance imaging, genetics, 35:137, 40:49
 magnetic resonance imaging, hippocampus, 35:1, 35:137
 magnetic resonance imaging, T2 hyperintense foci, 40:239
 magnetic resonance imaging, tardive dyskinesia, 40:157, 40:239
 magnetic resonance imaging, temporal horn volume, 35:1
 magnetic resonance imaging, temporal lobe, 35:1, 35:137
 magnetic resonance imaging, third ventricle, 40:49
 magnetic resonance imaging, ventricular size, 35:137, 40:49, 40:203
 magnetic resonance spectroscopy, fluphenazine, 35:107
 magnetic resonance spectroscopy, pharmacokinetics, 35:107
 measurement reliability, glucose metabolism, 40:11
 measurement reliability, positron emission tomography, 40:11
 measurement reliability, relative vs. absolute metabolic rate, 40:11
 neuroleptics, basal ganglia, 40:115
 neuroleptics, frontal lobe, 40:115
 neuroleptics, glucose, 40:115
 neuroleptics, positron emission tomography, 40:115
 neuropathology, brain stem reticular formation, 40:31

Schizophrenia continued

neuropathology, locus ceruleus, 40:31
 neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
 neuropathology, pedunculopontine nucleus, 40:31
 neuropsychology, blood flow, 40:253
 neuropsychology, Wisconsin Card Sort Test, 40:253
 never-medicated patients, apomorphine, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, glucose metabolism, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, temporal lobe, 40:135
 nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
 nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
 nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, post-mortem, 40:31
 pedunculopontine nucleus, brain stem reticular formation, 40:31
 pedunculopontine nucleus, locus ceruleus, 40:31
 pedunculopontine nucleus, neuropathology, 40:31
 pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 pharmacokinetics, fluphenazine, 35:107
 pharmacokinetics, magnetic resonance spectroscopy, 35:107
 positron emission tomography, anxiety, 40:101
 positron emission tomography, apomorphine, 40:135
 positron emission tomography, basal ganglia, 40:115
 positron emission tomography, frontal lobe, 40:101, 40:115, 40:135
 positron emission tomography, glucose metabolism, 40:11, 40:101, 40:115, 40:135
 positron emission tomography, haloperidol, 40:115

Schizophrenia continued

- positron emission tomography, homovanillic acid, 40:101
- positron emission tomography, measurement reliability, 40:11
- positron emission tomography, neuroleptics, 40:115
- positron emission tomography, never-medicated patients, 40:135
- positron emission tomography, prolactin, 40:101
- positron emission tomography, relative vs. absolute metabolic rate, 40:11
- positron emission tomography, temporal lobe, 40:135
- positron emission tomography, thiothixene, 40:115
- post-mortem examination, Alzheimer's disease, 35:149
- post-mortem examination, astrocytosis, 35:149
- post-mortem examination, dentate gyrus, 35:149
- post-mortem examination, entorhinal cortex, 35:149
- post-mortem examination, hippocampus, 35:149
- post-mortem, nicotinamide adenosine dinucleotide phosphate, 40:31
- prolactin, anxiety, 40:101
- prolactin, frontal lobe, 40:101
- prolactin, glucose metabolism, 40:101
- prolactin, homovanillic acid, 40:101
- prolactin, positron emission tomography, 40:101
- relative vs. absolute metabolic rate, glucose metabolism, 40:11
- relative vs. absolute metabolic rate, measurement reliability, 40:11
- relative vs. absolute metabolic rate, positron emission tomography, 40:11
- stability after psychosis onset, computed tomography, 40:21
- stability after psychosis onset, ventricular size, 40:21
- symptom severity, blood flow, 35:27
- symptom severity, frontal lobe, 35:27
- T2 hyperintense foci, magnetic resonance imaging, 40:239
- T2 hyperintense foci, tardive dyskinesia, 40:239
- tardive dyskinesia, basal ganglia, 40:157
- tardive dyskinesia, magnetic resonance imaging, 40:157

Schizophrenia continued

- tardive dyskinesia, magnetic resonance imaging, 40:239
- tardive dyskinesia, T2 hyperintense foci, 40:239
- temporal horn volume, amygdala, 35:1
- temporal horn volume, hippocampus, 35:1
- temporal horn volume, magnetic resonance imaging, 35:1
- temporal horn volume, temporal lobe, 35:1
- temporal lobe, amygdala, 35:1, 35:137
- temporal lobe, apomorphine, 40:135
- temporal lobe, frontal lobe, 40:135
- temporal lobe, genetics, 35:137
- temporal lobe, glucose metabolism, 40:135
- temporal lobe, hippocampus, 35:1
- 35:137
- temporal lobe, magnetic resonance imaging, 35:1, 35:137
- temporal lobe, never-medicated patients, 40:135
- temporal lobe, positron emission tomography, 40:135
- temporal lobe, temporal horn volume, 35:1
- temporal lobe, ventricular size, 35:137
- thiothixene, positron emission tomography, 40:115
- third ventricle, cranial size, 40:49
- third ventricle, genetics, 40:49
- third ventricle, magnetic resonance imaging, 40:49
- third ventricle, ventricular size, 40:49
- ventricle-brain ratio, admixture analysis, 35:61
- ventricle-brain ratio, computed tomography, 35:61
- ventricle-brain ratio, genetics, 35:61
- ventricular size, amygdala, 35:137
- ventricular size, blood-brain barrier, 40:203
- ventricular size, computed tomography, 40:21
- ventricular size, cortical sulcal enlargement, 40:203
- ventricular size, cranial size, 40:49
- ventricular size, gadolinium-DPTA, 40:203
- ventricular size, genetics, 35:137
- ventricular size, genetics, 40:49
- ventricular size, hippocampus, 35:137
- ventricular size, magnetic resonance imaging, 35:137, 40:49, 40:203
- ventricular size, stability after psychosis onset, 40:21
- ventricular size, temporal lobe, 35:137
- ventricular size, third ventricle, 40:49

Schizophrenia continued

Wisconsin Card Sort Test, blood flow, 40:253

Wisconsin Card Sort Test, neuropsychology, 40:253

Serotonin

clomipramine, electroencephalographic topography, 40:91

clomipramine, evoked potentials, 40:91

clomipramine, fluoxetine, 40:91

clomipramine, laterality, 40:91

clomipramine, P300, 40:91

electroencephalographic topography,

clomipramine, 40:91

electroencephalographic topography, evoked potentials, 40:91

electroencephalographic topography,

fluoxetine, 40:91

electroencephalographic topography,

laterality, 40:91

electroencephalographic topography, P300, 40:91

evoked potentials, clomipramine, 40:91

evoked potentials, electroencephalographic topography, 40:91

evoked potentials, fluoxetine, 40:91

evoked potentials, laterality, 40:91

evoked potentials, P300, 40:91

fluoxetine, clomipramine, 40:91

fluoxetine, electroencephalographic topography, 40:91

fluoxetine, evoked potentials, 40:91

fluoxetine, laterality, 40:91

fluoxetine, P300, 40:91

laterality, clomipramine, 40:91

laterality, electroencephalographic topography, 40:91

laterality, evoked potentials, 40:91

laterality, fluoxetine, 40:91

laterality, P300, 40:91

P300, clomipramine, 40:91

P300, electroencephalographic topography, 40:91

P300, evoked potentials, 40:91

P300, fluoxetine, 40:91

P300, laterality, 40:91

Sleep

affective disorder, frontal lobe, 40:247

affective disorder,

hexamethylpropyleneamineoxime (HMPAO), 40:247

affective disorder, limbic system, 40:247

affective disorder, single photon emission computed tomography, 40:247

affective disorder, sleep deprivation, 40:247

Sleep continued

arecoline, electroencephalographic topography, 35:91

arecoline, polysomnography, 35:91

electroencephalographic topography, arecoline, 35:91

electroencephalographic topography, polysomnography, 35:91

frontal lobe, affective disorder, 40:247

frontal lobe, hexamethylpropyleneamineoxime (HMPAO), 40:247

frontal lobe, limbic system, 40:247

frontal lobe, single photon emission

computed tomography, 40:247

frontal lobe, sleep deprivation, 40:247

hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247

hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247

hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247

hexamethylpropyleneamineoxime (HMPAO), single photon emission computed

tomography, 40:247

sleep deprivation, 40:247

tomography, 40:247

limbic system, affective disorder, 40:247

limbic system, frontal lobe, 40:247

limbic system, hexamethylpropyleneamineoxime (HMPAO), 40:247

limbic system, single photon emission

computed tomography, 40:247

limbic system, sleep deprivation, 40:247

polysomnography, arecoline, 35:91

polysomnography, electroencephalographic topography, 35:91

single photon emission computed tomography, affective disorder, 40:247

single photon emission computed tomography, frontal lobe, 40:247

single photon emission computed tomography, hexamethylpropyleneamineoxime (HMPAO), 40:247

single photon emission computed

tomography, limbic system, 40:247

single photon emission computed

tomography, sleep deprivation, 40:247

sleep deprivation, affective disorder, 40:247

sleep deprivation, frontal lobe, 40:247

sleep deprivation, hexamethylpropyleneamineoxime (HMPAO), 40:247

sleep deprivation, limbic system, 40:247

sleep deprivation, single photon emission computed tomography, 40:247

SPECT (Single photon emission tomography)

- affective disorder, frontal lobe, 40:247
- affective disorder, hexamethylpropyleneamineoxime (HMPAO), 40:247
- affective disorder, limbic system, 40:247
- affective disorder, sleep, 40:247
- affective disorder, sleep deprivation, 40:247
- Alzheimer's disease, blood flow, 40:167
- Alzheimer's disease, cortical circumferential analysis, 40:167
- Alzheimer's disease, iodoamphetamine, 40:167
- blood flow, Alzheimer's disease, 40:167
- blood flow, cortical circumferential analysis, 40:167
- blood flow, iodoamphetamine, 40:167
- cortical circumferential analysis, Alzheimer's disease, 40:167
- cortical circumferential analysis, blood flow, 40:167
- cortical circumferential analysis, iodoamphetamine, 40:167
- frontal lobe, affective disorder, 40:247
- frontal lobe, hexamethylpropyleneamineoxime (HMPAO), 40:247
- frontal lobe, limbic system, 40:247
- frontal lobe, sleep deprivation, 40:247
- hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
- hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
- hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
- iodoamphetamine, Alzheimer's disease, 40:167
- iodoamphetamine, blood flow, 40:167
- iodoamphetamine, cortical circumferential analysis, 40:167
- limbic system, affective disorder, 40:247
- limbic system, frontal lobe, 40:247
- limbic system, hexamethylpropyleneamineoxime (HMPAO), 40:247
- limbic system, sleep deprivation, 40:247
- sleep, affective disorder, 40:247
- sleep deprivation, affective disorder, 40:247
- sleep deprivation, frontal lobe, 40:247
- sleep deprivation, hexamethylpropyleneamineoxime (HMPAO), 40:247
- sleep deprivation, limbic system, 40:247
- sleep deprivation, sleep, 40:247
- sleep, frontal lobe, 40:247

SPECT (Single photon emission tomography)

- continued
- sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
- sleep, limbic system, 40:247
- sleep, sleep deprivation, 40:247
- Substance abuse**
- alpha power, Beck Depression Scale, 35:95
- alpha power, cocaine, 35:95
- alpha power, electroencephalographic topography, 35:95
- Beck Depression Scale, alpha power, 35:95
- Beck Depression Scale, cocaine, 35:95
- Beck Depression Scale, electroencephalographic topography, 35:95
- cocaine, alpha power, 35:95
- cocaine, Beck Depression Scale, 35:95
- cocaine, electroencephalographic topography, 35:95
- electroencephalographic topography, alpha power, 35:95
- electroencephalographic topography, Beck Depression Scale, 35:95
- electroencephalographic topography, cocaine, 35:95
- Tardive dyskinesia**
- basal ganglia, magnetic resonance imaging, 40:157
- basal ganglia, schizophrenia, 40:157
- magnetic resonance imaging, basal ganglia, 40:157
- magnetic resonance imaging, schizophrenia, 40:157, 40:239
- magnetic resonance imaging, T2 hyperintense foci, 40:239
- schizophrenia, basal ganglia, 40:157
- schizophrenia, magnetic resonance imaging, 40:157, 40:239
- schizophrenia, T2 hyperintense foci, 40:239
- T2 hyperintense foci, magnetic resonance imaging, 40:239
- T2 hyperintense foci, schizophrenia, 40:239
- Temporal lobe**
- amygdala, genetics, 35:137
- amygdala, hippocampus, 35:1, 35:137
- amygdala, magnetic resonance imaging, 35:1, 35:137
- amygdala, schizophrenia, 35:1, 35:137
- amygdala, temporal horn volume, 35:1
- amygdala, ventricular size, 35:137
- apomorphine, frontal lobe, 40:135
- apomorphine, glucose metabolism, 40:135
- apomorphine, never-medicated patients, 40:135

Temporal lobe continued

apomorphine, positron emission tomography, 40:135
 apomorphine, schizophrenia, 40:135
 frontal lobe, apomorphine, 40:135
 frontal lobe, glucose metabolism, 40:135
 frontal lobe, never-medicated patients, 40:135
 frontal lobe, positron emission tomography, 40:135
 frontal lobe, schizophrenia, 40:135
 genetics, amygdala, 35:137
 genetics, hippocampus, 35:137
 genetics, magnetic resonance imaging, 35:137
 genetics, schizophrenia, 35:137
 genetics, ventricular size, 35:137
 glucose metabolism, apomorphine, 40:135
 glucose metabolism, frontal lobe, 40:135
 glucose metabolism, never-medicated patients, 40:135
 glucose metabolism, positron emission tomography, 40:135
 glucose metabolism, schizophrenia, 40:135
 hippocampus, amygdala, 35:1, 35:137
 hippocampus, genetics, 35:137
 hippocampus, magnetic resonance imaging, 35:1, 35:137
 hippocampus, schizophrenia, 35:1, 35:137
 hippocampus, temporal horn volume, 35:1
 hippocampus, ventricular size, 35:137
 magnetic resonance imaging, amygdala, 35:1, 35:137
 magnetic resonance imaging, genetics, 35:137
 magnetic resonance imaging, hippocampus, 35:1, 35:137
 magnetic resonance imaging, schizophrenia, 35:1, 35:137
 magnetic resonance imaging, temporal horn volume, 35:1
 magnetic resonance imaging, ventricular size, 35:137
 never-medicated patients, apomorphine, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, glucose metabolism, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, schizophrenia, 40:135
 positron emission tomography, apomorphine, 40:135

Temporal lobe continued

positron emission tomography, frontal lobe, 40:135
 positron emission tomography, glucose metabolism, 40:135
 positron emission tomography, never-medicated patients, 40:135
 positron emission tomography, schizophrenia, 40:135
 schizophrenia, amygdala, 35:1, 35:137
 schizophrenia, apomorphine, 40:135
 schizophrenia, frontal lobe, 40:135
 schizophrenia, genetics, 35:137
 schizophrenia, glucose metabolism, 40:135
 schizophrenia, hippocampus, 35:1, 35:137
 schizophrenia, magnetic resonance imaging, 35:1, 35:137
 schizophrenia, never-medicated patients, 40:135
 schizophrenia, positron emission tomography, 40:135
 schizophrenia, temporal horn volume, 35:1
 schizophrenia, ventricular size, 35:137
 temporal horn volume, amygdala, 35:1
 temporal horn volume, hippocampus, 35:1
 temporal horn volume, magnetic resonance imaging, 35:1
 temporal horn volume, schizophrenia, 35:1
 ventricular size, amygdala, 35:137
 ventricular size, genetics, 35:137
 ventricular size, hippocampus, 35:137
 ventricular size, magnetic resonance imaging, 35:137
 ventricular size, schizophrenia, 35:137
Tetrahydrocannabinol
 glucose metabolism, positron emission tomography, 40:69
 positron emission tomography, glucose metabolism, 40:69
Thiothixene
 positron emission tomography, schizophrenia, 40:115
 schizophrenia, positron emission tomography, 40:115
Ventricle-brain ratio
 admixture analysis, computed tomography, 35:61
 admixture analysis, genetics, 35:61
 admixture analysis, schizophrenia, 35:61
 aging, Alzheimer's disease, 35:115
 aging, cognition, 35:115
 aging, computed tomography, 35:115
 aging, hippocampus, 35:15
 aging, limbic system, 35:15

Ventricle-brain ratio continued

aging, magnetic resonance imaging, 35:15
 aging, Mini-Mental State Examination, 35:115
 aging, Wechsler Adult Intelligence Scale, 35:115
 alcoholism, computed tomography, 40:1
 alcoholism, measurement reliability, 40:1
 Alzheimer's disease, aging, 35:115
 Alzheimer's disease, cognition, 35:115
 Alzheimer's disease, computed tomography, 35:115
 Alzheimer's disease, Mini-Mental State Examination, 35:115
 Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115
 amygdala, genetics, 35:137
 amygdala, hippocampus, 35:137
 amygdala, magnetic resonance imaging, 35:137
 amygdala, schizophrenia, 35:137
 amygdala, temporal lobe, 35:137
 blood-brain barrier, cortical sulcal enlargement, 40:203
 blood-brain barrier, gadolinium-DPTA, 40:203
 blood-brain barrier, magnetic resonance imaging, 40:203
 blood-brain barrier, schizophrenia, 40:203
 cognition, aging, 35:115
 cognition, Alzheimer's disease, 35:115
 cognition, computed tomography, 35:115
 cognition, Mini-Mental State Examination, 35:115
 cognition, Wechsler Adult Intelligence Scale, 35:115
 computed tomography, admixture analysis, 35:61
 computed tomography, aging, 35:115
 computed tomography, alcoholism, 40:1
 computed tomography, Alzheimer's disease, 35:115
 computed tomography, cognition, 35:115
 computed tomography, genetics, 35:61
 computed tomography, measurement reliability, 40:1
 computed tomography, Mini-Mental State Examination, 35:115
 computed tomography, schizophrenia, 35:61, 40:21
 computed tomography, stability after psychosis onset, 40:21
 computed tomography, Wechsler Adult Intelligence Scale, 35:115

Ventricle-brain ratio continued

cortical sulcal enlargement, blood-brain barrier, 40:203
 cortical sulcal enlargement, gadolinium-DPTA, 40:203
 cortical sulcal enlargement, magnetic resonance imaging, 40:203
 cortical sulcal enlargement, schizophrenia, 40:203
 cranial size, genetics, 40:49
 cranial size, magnetic resonance imaging, 40:49
 cranial size, schizophrenia, 40:49
 cranial size, third ventricle, 40:49
 gadolinium-DPTA, blood-brain barrier, 40:203
 gadolinium-DPTA, cortical sulcal enlargement, 40:203
 gadolinium-DPTA, magnetic resonance imaging, 40:203
 gadolinium-DPTA, schizophrenia, 40:203
 genetics, admixture analysis, 35:61
 genetics, amygdala, 35:137
 genetics, computed tomography, 35:61
 genetics, cranial size, 40:49
 genetics, hippocampus, 35:137
 genetics, magnetic resonance imaging, 35:137, 40:49
 genetics, schizophrenia, 35:61, 35:137, 40:49
 genetics, temporal lobe, 35:137
 genetics, third ventricle, 40:49
 hippocampus, aging, 35:15
 hippocampus, amygdala, 35:137
 hippocampus, genetics, 35:137
 hippocampus, limbic system, 35:15
 hippocampus, magnetic resonance imaging, 35:15, 35:137
 hippocampus, schizophrenia, 35:137
 hippocampus, temporal lobe, 35:137
 limbic system, aging, 35:15
 limbic system, hippocampus, 35:15
 limbic system, magnetic resonance imaging, 35:15
 magnetic resonance imaging, aging, 35:15
 magnetic resonance imaging, amygdala, 35:137
 magnetic resonance imaging, blood-brain barrier, 40:203
 magnetic resonance imaging, cortical sulcal enlargement, 40:203
 magnetic resonance imaging, cranial size, 40:49
 magnetic resonance imaging, gadolinium-DPTA, 40:203

Ventricle-brain ratio continued

magnetic resonance imaging, genetics, 35:137
 magnetic resonance imaging, genetics, 40:49
 magnetic resonance imaging, hippocampus, 35:15, 35:137
 magnetic resonance imaging, limbic system, 35:15
 magnetic resonance imaging, ratio measurement reliability, 40:79
 magnetic resonance imaging, schizophrenia, 35:137, 40:49, 40:203
 magnetic resonance imaging, temporal lobe, 35:137
 magnetic resonance imaging, third ventricle, 40:49
 measurement reliability, alcoholism, 40:1
 measurement reliability, computed tomography, 40:1
 Mini-Mental State Examination, aging, 35:115
 Mini-Mental State Examination, Alzheimer's disease, 35:115
 Mini-Mental State Examination, cognition, 35:115
 Mini-Mental State Examination, computed tomography, 35:115
 Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
 ratio measurement reliability, magnetic resonance imaging, 40:79
 schizophrenia, admixture analysis, 35:61
 schizophrenia, amygdala, 35:137
 schizophrenia, blood-brain barrier, 40:203
 schizophrenia, computed tomography, 35:61, 40:21
 schizophrenia, cortical sulcal enlargement, 40:203

Ventricle-brain ratio continued

schizophrenia, cranial size, 40:49
 schizophrenia, gadolinium-DPTA, 40:203
 schizophrenia, genetics, 35:61, 35:137
 40:49
 schizophrenia, hippocampus, 35:137
 schizophrenia, magnetic resonance imaging, 35:137, 40:49, 40:203
 schizophrenia, stability after psychosis onset, 40:21
 schizophrenia, temporal lobe, 35:137
 schizophrenia, third ventricle, 40:49
 stability after psychosis onset, computed tomography, 40:21
 stability after psychosis onset, schizophrenia, 40:21
 temporal lobe, amygdala, 35:137
 temporal lobe, genetics, 35:137
 temporal lobe, hippocampus, 35:137
 temporal lobe, magnetic resonance imaging, 35:137
 temporal lobe, schizophrenia, 35:137
 third ventricle, cranial size, 40:49
 third ventricle, genetics, 40:49
 third ventricle, magnetic resonance imaging, 40:49
 third ventricle, schizophrenia, 40:49
 Wechsler Adult Intelligence Scale, aging, 35:115
 Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115
 Wechsler Adult Intelligence Scale, cognition, 35:115
 Wechsler Adult Intelligence Scale, computed tomography, 35:115
 Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115